THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

CURRICULUM VITAE

NAME AND DEGREES Tapan M. Kadia, M.D.

OFFICE ADDRESS The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
FC4.3058
Unit 428
Houston, TX 77030

CURRENT APPOINTMENTS

Jan 2024–Present	Director, T-cell LPD and Aplastic Anemia Program Leukemia Cancer Medicine The University of Texas MD Anderson Cancer Center
Sep 2021–Present	Professor Leukemia M.D. Anderson Cancer Center
Sep 2019–Present	Co-Leader, AML Section The University of Texas MD Anderson Cancer Center, Department of Leukemia
Sep 2019–Present	Co-Leader, Section of Developmental Therapeutics The University of Texas MD Anderson Cancer Center, Department of Leukemia

LICENSES AND CERTIFICATIONS

Oct 2018–Present	Hematology, American Board of Internal Medicine Board Certification
Oct 2008–Present	Medical Oncology, American Board of Internal Medicine Board Certification
Dec 2004–Feb 28, 2026	Texas State Board of Medical Examiners Licensure, M0120
Aug 2004–Present	Internal Medicine, American Board of Internal Medicine Board Certification

EDUCATION, EXPERIENCE, AND SERVICE

DEGREES OBTAINED

Jul 2001	MD Robert Wood Johnson Medical School; Piscataway, New Jersey
Jul 1998	BA in Bachelor of Arts Rutgers University; New Brunswick, New Jersey

POSTGRADUATE TRAINING

Jul 2005–Jun 2008	Clinical Fellowship, Hematology/Oncology

	MD Anderson Cancer Center
Jul 2004–Jun 2005	Chief Residency Baylor College of Medicine Affiliated Hospitals; Houston, Texas
Jul 2002–Jun 2004	Clinical Residency Baylor College of Medicine Affiliated Hospitals; Houston, Texas
Jul 2001–Jun 2002	Clinical Internship Baylor College of Medicine Affiliated Hospitals; Houston, Texas

FACULTY ACADEMIC APPOINTMENTS

Sep 2021–Present	Professor Leukemia M.D. Anderson Cancer Center
Sep 2015–Aug 2021	Associate Professor Leukemia The University of Texas MD Anderson Cancer Center
Jul 2008–Sep 2015	Assistant Professor Leukemia The University of Texas MD Anderson Cancer Center

OTHER PROFESSIONAL POSITIONS

Sep 2019–Present	Co-Leader, AML Section The University of Texas MD Anderson Cancer Center, Department of Leukemia; Houston, TX
Sep 2019–Present	Co-Leader, Section of Developmental Therapeutics The University of Texas MD Anderson Cancer Center, Department of Leukemia; Houston, TX
Sep 2014–Aug 2015	Member EPIC Rollout Committee; Houston, TX

ADMINISTRATIVE LEADERSHIP POSITIONS

Jan 2020–Present	Committee Vice Chair Data Safety Monitoring Committee (DSMC) - MDACC; Houston, TX
Sep 2019–Present	Fellowship Program Associate Director Leukemia MD Anderson Cancer Center Leukemia Fellowship Program; Houston, TX
Sep 2019–Present	Committee Chair MD Anderson Cancer Center - Board Review in Hematology Oncology; Houston, TX
Jan 2014–Present	Committee Chair Cancer Medicine Leukemia New Patient Conference, The University of Texas MD Anderson Cancer Center; Houston, TX

HONORS AND PRIZES

2022–2024	Ashbel Smith Professorship UT MD Anderson Cancer Center
2006	Recipient of The Paul Calabresi Clinical Oncology Award-K12 Grant
2006	AACR/ASCO Workshop Methods in Clinical Cancer Research Vail Vail
2006	AACR/ASCO Workshop Molecular Biology in Clinical Oncology Aspen

2006	FOREM Lymphoma Research Award, Runner up
2004	Chief Residency, Internal Medicine Baylor College of Medicine
2000	Articulated BA/MD Program
2000	Member, Golden Key National Honor Society
2000	Member, Phi Beta Kappa Honor Society
2000	Member, Phi Eta Sigma Honor Society
2000	Recipient of The Waksman Fellowship for Undergraduate Research
2000	UMDNJ Research Fellowship
2000	Dean's List, Rutgers College
1998	Norman Reitman Scholar
1995–1996	Rutgers College Award of Excellence

COMMITTEE SERVICE

Mar 2021–Sep 2022	Elected Member, Institutional Committee PRS Budget & Finance Comittee The University of Texas MD Anderson Cancer Center
Aug 2020–Present	Vice Chair, Institutional Committee DSMC The University of Texas MD Anderson Cancer Center
Mar 2020–Present	Member, Institutional Committee ICU Utilization Committee The University of Texas MD Anderson Cancer Center
Mar 2020–Present	Member, Institutional Committee Institutional Goals of Care Committee The University of Texas MD Anderson Cancer Center
Sep 2016–Present	Member, Institutional Committee MD Anderson Physicians Network Multidisciplinary Planning Conferences (MPC) The University of Texas MD Anderson Cancer Center
Jan 2016–Present	Member, Institutional Committee Institutional Committee on Sepsis The University of Texas MD Anderson Cancer Center
Jan 2016–Jan 2022	Member, Institutional Committee Utilization Review Committee The University of Texas MD Anderson Cancer Center
Sep 2013–Sep 2021	Member, Institutional Committee Credentials Committee, MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center
Jan 2012–Sep 2019	Co-Director, Institutional Committee MD Anderson Hematology and Medical Oncology Board Review Steering Committee The University of Texas MD Anderson Cancer Center
Sep 2011–Sep 2017	Member, Institutional Committee Faculty Senate The University of Texas MD Anderson Cancer Center
Sep 2011–Sep 2017	Member, Institutional Committee Clinical Affairs Subcommittee, Faculty Senate, MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center

Jul 2010–Sep 2019	Member, Institutional Committee Clinical Research Committee (CRC, SRC), MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center
Jan 2010–Present	Member, Leukemia Department Representative, Institutional Committee Fellowship Steering Committee The University of Texas MD Anderson Cancer Center

PROFESSIONAL SOCIETIES

Jan 01, 2013–Present	American Association of Cancer Research (AACR) Jan 2013–Present Member
Oct 01, 2012–Present	Society of Hematologic Oncology Houston, TX Oct 2012–Present Member
Jan 01, 2000–Present	American Society of Hematology (ASH) Jan 2000–Present Member
Jan 01, 2000–Present	American Society of Clinical Oncology (ASCO) Jan 2000–Present Member

EDITORIAL ACTIVITIES

2019–Present	Associate Editor Hematology
2017–Present	Editoria Review Board Memeber Haematologica
2017–Present	Editorial Review Board Member Clinical Lymphoma Myeloma and Leukemia

PEER REVIEW ACTIVITIES

2014–Present	Journal Reviewer (ad hoc Reviewer) Blood Journal
2014–Present	Journal Reviewer (ad hoc Reviewer) Blood
2012–Present	Journal Reviewer (ad hoc Reviewer) British Journal Of Haematology
2011–Present	Journal Reviewer (ad hoc Reviewer) Leukemia and Lymphoma
2010–Present	Journal Reviewer (ad hoc Reviewer) Haematologica
2009–Present	Journal Reviewer (ad hoc Reviewer) Cancer

RESEARCH PROJECTS

GRANTS, CONTRACTS, AND SPONSORED RESEARCH AGREEMENTS

Active, Sep 26, 2018–Present	A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

	M.D. Anderson Cancer Center, 2018-0484 Principal Investigator ($ 571,120 incl. indirect costs; $571,120/year)
Active, Oct 19, 2015–Nov 30, 2024	PD-1 inhibition with Nivolumab for the Treatment of Patients with Acute Myeloid Leukemia in Remission at High Risk for Relapse BMS Principal Investigator ($ 28,444 incl. indirect costs; $3,121/year)
Past, Jan 01, 2020–Dec 31, 2022	Pre-Clinical Efficacy of CDK7 inhibitor-based combinations against AML including Post-Myeloproliferative Neoplasm (post-MPN) sAML Cells Basic Translational Research, IRG Principal Investigator ($ 75,000 incl. indirect costs; $25,000/year)
Past, Sep 01, 2018–Aug 31, 2023	SPORE in Leukemia Project 2: Anti-PR1 for Myeloid Leukemia NIH/NCI, P50CA100632 CO-I ($ 172,616 incl. indirect costs; $34,523/year)
Past, Jul 01, 2017–Jun 30, 2023	A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Contract, NIH/NCI, 5-P50-CA171963-05 Co-Principal Investigator ($ 31,250 incl. indirect costs; $5,208/year)
Past, Jun 01, 2014–Jul 30, 2022	Phase II Study of Maintenance Lenalidomide in Patients with High Risk AML in Remission Celgene Principal Investigator ($ 320,000 incl. indirect costs; $39,208/year)
Past, Sep 01, 2008–Aug 31, 2010	Paul Calabresi Clinial Oncology Award Program/Faculty trainee NIH/NCI, 5 K12 CA088084-09 Project Leader ($ 156,095 incl. indirect costs; $78,048/year)
Past, Dec 10, 2006–Aug 31, 2008	Fellow Trainee for Translational Research Faculty Development Committee - Paul Calabresi Clinical Oncology Award Program NIH/NCI, 5 K12 CA088084-08 Project Leader ($ 16,400 incl. indirect costs; $9,517/year)
Past, 2005–2008	Phase I Study of Suberoylanilide Hydroxamic Acid in Combination with Idarubicin for Patients with Relapsed Leukemia NIH/NCI, CTEP Study 2005-0031/UO1 CA062461 Principal Investigator
Not funded	Lenalidomide Maintenance Therapy in Patients with High-Risk Acute Myeloid Leukemia MDACC R. Lee Clark Fellows Award, 01 Principal Investigator ($ 100,000 incl. indirect costs; $100,000/year)
Not funded, Oct 01, 2021–Sep 30, 2024	Novel targeted therapies of AML stem-progenitor cells. Leukemia and Lymphoma Society, FP00013617 Principal Investigator ($ 539,541 incl. indirect costs; $179,847/year)
Not funded, Apr 01, 2012–Mar 31, 2014	Measuring the therapeutic index of treating DVT in thrombocytopenic AML patients R21, NIH/NCI CO-I ($ 250,000 incl. indirect costs; $125,000/year)
Not funded, Jul 01, 2011–Jun 30, 2014	CDA: "Targeting B-Cell Receptor Signaling in the Treatment of CLL” American Society of Clinical Oncology (ASCO), 01 Principal Investigator ($ 187,398 incl. indirect costs; $62,466/year)
Not funded, Jul 01, 2008–Jun 30, 2009	YIA: "Evaluating the Combination of a Histone Deacetylase Inhibitor Vorinostat with the Topoisomerase II Inhibitor Idarubicin in Acute Leukemia" American Society of Clinical Oncology (ASCO), 01 Principal Investigator ($ 47,500 incl. indirect costs; $47,500/year)
Unknown, Mar 01, 2022–Feb 28, 2026	Novel targeted therapies of AML

Cancer Prevention & Research Institute of Texas (CPRIT), FP00014071
Principal Investigator ($ 1,877,100 incl. indirect costs; $469,275/year)

CLINICAL PROTOCOLS

Active, 2022–Present — Ph 1/2 ABC008 in T-LGLL, 2022-0600
Principal Investigator

Active, 2021–Present — Ph1b/II APG-2575 + azacitidine in AML, MPAL, CMML, and HR-MDS, 2021-0566
Principal Investigator

Active, 2021–Present — Ph1/2 REGN7257 in patients with severe aplastic anemia refractory or relapsed on immunosuppressive therapy, 2021-0245
Principal Investigator

Active, 2020–Present — Ph1 CC-96191 in Relapsed or Refractory AML, 2021-0047
Principal Investigator

Active, 2020–Present — Fludarabine, Cytarabine, and Pegcristantaspase in R/R Leukemias, 2020-0434
Principal Investigator ($ 1,242,000 incl. indirect costs; $1,242,000/year)

Active, 2020–Present — A PHASE IIA STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND EFFICACY OF APG-115 AS A SINGLE AGENT OR IN COMBINATION WITH APG-2575 IN SUBJECTS WITH RELAPSED/REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA (R/R T-PLL), 2020-1155
Principal Investigator

Active, 2020–Present — Ph1/2 ASP7517 in R/R AML and R/R MDS, 2021-0530
Principal Investigator

Active, 2020–Present — Ph1b/2 Uproleselan + Cladribine + Low-Dose Cytarabine in Treated Secondary AML, 2020-0988
Principal Investigator

Active, 2020–Present — Oral Decitabine in AML Maintenance, 2021-0237
Principal Investigator

Active, 2020–Present — Ph1b/2 APG-115 Alone or APG-115 + Aza in R/R AML, 2020-0422
Principal Investigator

Active, 2020–Present — Ph1 Tegavivint (BC-2059) in R/R AML, 2020-0616
Principal Investigator

Active, 2020–Present — Ph1 GFH009 in R/R Hematologic Malignancies, 2020-0689
Principal Investigator

Active, 2020–Present — Ph3 Glinpepimut-S vs. MD Choice for AML Maintenance, 2020-0252
Principal Investigator

Active, 2019–Present — PhII AZA + Venetoclax as Maintenance for HR-AML, 2019-0226
Principal Investigator ($ 1,625,000 incl. indirect costs; $1,625,000/year)

Active, 2019–Present	Ph1b Itacitinib + Alemtuzumab in T-PLL, 2019-0054 Principal Investigator ($ 266,648 incl. indirect costs; $266,648/year)
Active, 2019–Present	Ph3 Randomized DFP-10917 V. Non-intensive OR Intensive Reinduction for AML in 2nd or 3rd Salvage, 2019-0357 Principal Investigator ($ 852,382 incl. indirect costs; $852,382/year)
Active, 2018–Present	Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation with Cladribine Plus LDAC Alternating with 5-Azacitidine in Patients with Untreated AML, 2018-0020 Principal Investigator
Active, 2017–Present	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory Leukemias, 2016-0772 Principal Investigator ($ 469,937 incl. indirect costs; $469,937/year)
Active, 2017–Present	Phase II Study of CPX-351 in Combination with Venetoclax in Patients with Acute Myeloid Leukemia (AML) MD Anderson, 2017-1055 Principal Investigator ($ 1,150,000 incl. indirect costs; $1,150,000/year)
Active, 2014–Present	Phase I Study of Hu8F4 in Patients with Advanced Hematologic Malignancies, 2014-0057 Principal Investigator
Active, 2011–Present	Phase II Study Of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine In Patients With Untreated AML Or High-Risk MD Anderson, 2011-0987 Study Chairman
Past, 2021–2023	Ph3 Venetoclax + Azacitidine versus Best Supportive Care as Maintenance Therapy with AML in First Remission (VIALE-M), 2021-0303 Principal Investigator
Past, 2020–2021	PUL-042/Placebo in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection, 2020-0405 Principal Investigator ($ 148,750 incl. indirect costs; $74,375/year)
Past, 2020–2022	PUL-042/Placebo in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2, 2020-0407 Principal Investigator
Past, 2019–2022	Ph1 JNJ-67571244 (CD33-CD3) in AML or MDS, 2019-0950 Principal Investigator ($ 1,221,250 incl. indirect costs; $305,312/year)
Past, 2019–2021	Strategic Alliance: 2009-1002 a Phase l/ll Combination Study of Sapacitabine in Acute Myeloiid Leukemia or Myelodysplastic Syndromes, 2009-1002 Principal Investigator ($ 954,375 incl. indirect costs; $318,125/year)
Past, 2019–2022	Ibrutinib + Venetoclax in T-PLL, 2019-1069 Principal Investigator ($ 40,626 incl. indirect costs; $10,156/year)

Past, 2018–2022	A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies, 2018-0484 Principal Investigator ($ 571,120 incl. indirect costs; $114,224/year)
Past, 2018–2023	Phase I Trial to Evaluate the Safety of CK0801 in Treatment of Bone Marrow Failure Syndromes, 2018-0010 Principal Investigator ($ 572,186 incl. indirect costs; $95,364/year)
Past, 2018	A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia, 2017-0776 Principal Investigator ($ 562,973 incl. indirect costs; $562,973/year)
Past, 2017–2023	A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma, 2016-1101 Study Chairman
Past, 2017–2018	Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody,Administered by Intravenous Infusion in Patients with RElapsed or RefractoryT-acute LymphoblasticLeukemia or T-lymphoblastic Lymphoma, 2016-0789 Study Chairman ($ 299,531 incl. indirect costs; $149,766/year)
Past, 2017–2023	A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in combination with Venetoclax in Subjects with Relapsed or Refrac, 2017-0702 Principal Investigator
Past, 2016–2017	Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase I.V. in Patients with Relapsed or Refractory Hematologic Malignancies, 2015-0807 Study Chairman
Past, 2015–2019	A Phase IB, Open-label Pilot Study Designed to Evaluate the Efficacy and Safety of BL-8040 followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects with Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS), 2015-0408 Study Chairman ($ 204,529 incl. indirect costs; $40,906/year)
Past, 2015–2016	A Phase 1 Study of KB003 in Subjects with Previously Treated Chronic Myelomonocytic Leukemia (CMML), 2015-0673 Study Chairman ($ 122,950 incl. indirect costs; $61,475/year)
Past, 2015–2023	PD-1 Inhibition with Nivolumab for the Treatment of Patients with Acute Myeloid Leukemia in Remission at High Risk for Relapse, 2015-0213 Study Chairman ($ 256,000 incl. indirect costs; $28,444/year)

Past, 2014–2022	Phase II Study of Lenalidomide Maintenance in Patients with High Risk AML in Remission., 2014-0116 Study Chairman ($ 251,700 incl. indirect costs; $27,967/year)
Past, 2012–2013	Compassionate Use Single Patient Study for treatment with Marqibo + Rituxan in a Patient with ALL, CIND12-0075 Study Chairman
Past, 2010–2015	A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients with Relapsed/ Refractory Lymphoid Malignancies, 2009-0717 Principal Investigator ($ 118,900 incl. indirect costs; $19,817/year)
Past, 2010–2013	A Phase II Study of Bafetinib(INNO-406) as Treatment for Patients with Relapsed or Refractory B- Cell Chronic Lymphocytic Leukemia (B-CLL), 2010-0175 Study Chairman
Past, 2005–2010	Phase I Study of Suberoylanilide Hydroxamic Acid in Combination with Idarubicin for Patients with Relapsed Leukemia, CTEP study 2005-0031/UO1 CA062461 Co-Investigator with Mentor (Razelle Kurzock PI)
Past, 2005–2011	Phase II study of combination of thymoglobulin, cyclosporine, methylprednisone, and GCSF in patients with newly diagnosed aplastic anemia or with hypoplastic or low/intermediate - 1 risk myelodysplastic syndrome, 2005-0115 Principal Investigator
Unknown, Sep 2024–Present	A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies, Kumquat Biosciences, Inc, 2024-1013 Principal Investigator
Unknown, 2024–Present	A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML), AVEO Pharmaceuticals, Inc., MDACC Protocol Number Principal Investigator
Unknown, 2018–Present	Evaluation of the prognostic impact of smoking status at diagnosis in patients with acute myeloid leukemia, PA18-0858 Principal Investigator
Unknown, 2018–Present	Phase I Study of C188-9 in Patients with Relapsed and Refractory Leukemias, 2018-0436 Principal Investigator
Unknown, 2018–Present	Viability and Function of T-lymphocytes in Patients with Leukemias and Bone Marrow Failure Disorders, PA18-0591 Principal Investigator

Unknown, 2017–Present	Clinical Outcomes in Adult Patients with Aplastic Anemia: A single Institution Experience, PA17-0265 Study Chairman
Unknown, 2016–Present	A Retrospective Review and Prospective Database of Patients with T-cell Prolynphocytic Leukemia (T-PLL), PA16-0709 Study Chairman
Unknown, 2014–Present	PHASE II STUDY OF CLADRIBINE PLUS IDARUBICIN PLUS CYTARABINE (ARAC) IN PATIENTS WITH AML, HR MDS, OR MYELOID BLAST PHASE OF CML., 2012-0648 Study Chairman
Unknown, 2012–Present	Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisone, and GCSF (Filgrastim or Pegfilgrastim) in Patients with Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS), 2012-0334 Study Chairman
Unknown, 2010–2016	Phase II Pilot Of Study Of Alemtuzumab In Patients With Low or INT - 1 Risk Meylodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T - Cell Large Granular Lymphocytic Leukemia, 2010-0187 Study Chairman

TEACHING AND TRAINING

FORMAL TEACHING, UNDER- THROUGH POST-GRADUATE

Jan 01, 2014–Present	M D Anderson, Baylor College of Medicine Hematology and Oncology Board Review Course, Lecturer and Member of Steering Committee The University of Texas MD Anderson Cancer Center
Jan 01, 2012–Present	Leukemia, MDS, Aplastic Anemia, Lecturer Formal Lectures The University of Texas MD Anderson Cancer Center
Jan 01, 2005–Sep 01, 2008	U.T. Internal Medicine Resident formal lectures on Oncologic Emergencies, Lecturer The University of Texas MD Anderson Cancer Center
Jan 01, 2004–Jan 01, 2005	Core Internal Medicine Chief Resident Lecture Series - Students and Residents, Lecturer Baylor College of Medicine

CLINICAL SUPERVISION AND TRAINING

Direct Supervision - Clinical Residents and Fellows, University of Texas Health Science Center

Kelly Casteel, MD

Direct Supervision - Clinical Residents and Fellows, The University of Texas MD Anderson Cancer Center

Fevzi Yalniz

Megan Dupuis

Mansour Alfaez

Hussein Abbas

Mahran Shoukier

Iman Abou Dalle

Roman Darwin

Direct Supervision - Clinical Residents and Fellows (Research and Clinical Mentor), MDACC

Rita Assi

Patrick Reville

Prajwal Boddu

Direct Supervision - Clinical Residents and Fellows (Research and Clinical Mentor), The University of Texas MD Anderson Cancer Center

Kunwha Kim

Direct Supervision - Clinical Residents and Fellows, The University Of Texas MD Anderson Cancer Center

Multiple trainees

Multiple trainees

FORMAL TEACHING OF PEERS

May 01, 2020 Personalizing Therapy: New and Emerging Therapeutic Agents in the Treatment of AML
Michigan State University; East Lansing, MI

Mar 03, 2017 Management of AYA Acute Lymphoblastic Leukemia
UT San Antonio Health Science Center; San Antonio, TX

Mar 14, 2015 Updates and Review in Leukemia from the American Society of Hematology Symposium
Stephenson Cancer Center, The University of Oklahoma; Oklahoma City, OK

Jan 04, 2015 State of the Art in the Treatment of AML
Baylor College of Medicine; Houston, TX

PRESENTATIONS & TALKS

LOCAL

Oct 16, 2014 Advances and Treatment of Myelodysplastic Syndrome(MDS)
Peer-reviewed conference presentation
MD Anderson Cancer Center

Sep 18, 2014 Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts
Peer-reviewed conference presentation
SOHO 2014; Houston, TX

REGIONAL

Jun 14, 2023 “Intensity’ With Efficacy in AML: Developing Modern, Intensive Upfront Platforms in Challenging Disease Presentations”
Peer-reviewed conference presentation (Presenter)
PeerView Institute; Virtual

Jan 23, 2023	Acute Myeloid Leukemia and Myelodysplastic Syndrome Peer-reviewed conference presentation (Presenter) AACR; Austin, TX
Jan 22, 2020	How Can Pathologic Assessment Be Optimized for Patients with AML? Personalizing Therapy in AML Peer-reviewed conference presentation (Presenter) Naples Hematopathlogy Meeting; Naple, FL
Aug 11, 2018	Leukemia in 2018 and Beyond Peer-reviewed conference presentation (Presenter) JAZZ; New York, NY
Oct 26, 2017	New Frontiers in the Management of Acute Myeloid Leukemia (AML): Exploring Emerging Treatment Options Peer-reviewed conference presentation (Presenter) NAMCP Fall Forum; Las Vegas, NV
Oct 18, 2014	Challenging Cases in Hematology - CML and CLL Peer-reviewed conference presentation (Presenter) CME
Apr 26, 2014	Chronic Myelogenous Leukemia Peer-reviewed conference presentation (Presenter) CME; Las Vegas, NV
Apr 26, 2014	Chronic Lymphocytic Leukemia Peer-reviewed conference presentation (Presenter) CME; Las Vegas, NV

NATIONAL

Jul 21, 2023	AML - Setting the Stage and Presession Survey Peer-reviewed conference presentation (Presenter) 7th Annual Live Medical Crossfire®: Hematologic Malignancies; New York, NY
Jul 06, 2023	Optimizing maintenance therapy in AML post-consolidation and post-transplant Peer-reviewed conference presentation (Presenter) AML-ALL US Focus Meeting 2023; La Jolla, CA
Apr 14, 2023	Phase I study of the T-cell receptor-like antibody Hu8F4 in patients with advanced hematologic malignancies Peer-reviewed conference presentation (Presenter) AACR; Orlando, FL
Mar 25, 2023	Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Peer-reviewed conference presentation (Presenter) Best of Heme; Vail, CO
Nov 15, 2022	Focus Forward: AML Patient Courses Peer-reviewed conference presentation (Presenter) Servier Pharmaceuticals; New Mexico
Sep 28, 2022	Non-Intensive Treatment of Elderly/Unfit Patients with AML Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology; Houston, TX
Dec 05, 2020	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Peer-reviewed conference presentation (Presenter) ASH

Dec 05, 2020	Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) Peer-reviewed conference presentation (Presenter) ASH
Sep 22, 2020	Treating Older Patinets with Newly Diagnosed AML Proeventi Peer-reviewed conference presentation (Presenter) SOHO 2nd Italian Conference; Rome
Jun 2019	EDUCATION SESSION: Less is More in the Treatment of Older Patients with AML Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
May 31, 2019	Leveraging Evidence to Optimize Applications of Novel Therapies in AML - Personalizing Therapy in AML Satellite Education Session Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Apr 02, 2019	Clinical Plenary Session Discussant: Phase III ADMIRAL Trial of Gilteritinib in R/R AML Peer-reviewed conference presentation (Presenter) American Association of Cancer Research (AACR); Atlanta, GA
Jun 02, 2018	Nivolumab Maintenance in high-risk Acute Myeloid Leukemia (AML) Patients Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Dec 05, 2017	Treating AYA ALL - The Adult Leukemia Experience Peer-reviewed conference presentation (Presenter) 2nd Annual Global AYA Congress; Atlanta, GA
Oct 27, 2017	New Frontiers in the Management of Acute Myeloid Leukemia (AML): Exploring Emerging Treatment Options Peer-reviewed conference presentation (Presenter) NAMCP - National Association of Managed Care Physicians; Las Vegas, NV
Sep 13, 2017	Understanding Risk in MDS, "The Good, the Bad, and the Ugly" Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology (SOHO); Houston, TX
Jun 06, 2017	Session Chair: Leukemia, MDS, Allogeneic SCT Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Jun 02, 2017	Outcomes with Lower Intensity Therapy in TP53-Mutated Acute Myeloid Leukemia (AML) Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Jan 14, 2017	Cladribine in AML Peer-reviewed conference presentation (Presenter) 8th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy; Jekyll Island, GA
Dec 04, 2015	Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia Peer-reviewed conference presentation (Presenter) American Society of Hematology; Orlando, FL
Dec 08, 2014	Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML) Peer-reviewed conference presentation (Presenter) American Society of Hematology; San Francisco, CA

Oct 16, 2014	Medical Oncology and Hematology 2014 Meeting, Advances and Treatment of MDS Peer-reviewed conference presentation (Presenter) Houston, TX
Jul 26, 2014	Update on Hematologic Malignancies for The Primary Care Physician Peer-reviewed conference presentation (Presenter) Texas Academy of Family Physicians 65th Annual Session; San Antonio, TX
Jan 25, 2014	ASH Update in Chronic Myeloid Leukemia Peer-reviewed conference presentation (Presenter) ASH; Orlando, FL
Sep 25, 2013	Malignant Hematology - Case and Topic Review Peer-reviewed conference presentation (Presenter) 2013 Comprehensive Board Review in Hematology and Medical Oncology; Houston, TX
Sep 22, 2012	MDS: Current Thinking of the Disease, Diagnosis and Treatment (Lower-Risk) Peer-reviewed conference presentation (Presenter) Aplastic Anemia & MDS International Foundation; Dallas, TX
Sep 22, 2012	Advances in MDS Treatment: What's on the Horizon Peer-reviewed conference presentation (Presenter) Aplastic Anemia & MDS International Foundation; Dallas, TX
Sep 2012	Malignant Hematology - Question and Case Review Peer-reviewed conference presentation (Presenter) MDACC
Sep 2011	Malignant Hematology - Question and Case Review Peer-reviewed conference presentation (Presenter) MDACC
Sep 2010	Malignant Hematology - Case and Topic Review Peer-reviewed conference presentation (Presenter) MDACC
Jan 23, 2010	What’s new in CML from American Society of Hematology (ASH) Meeting? Peer-reviewed conference presentation (Presenter) American Society of Hematology; Orlando, FL
Dec 07, 2009	Acute Myeloid Leukemia – Biology And Pathophysiology: Biologic and Clinical Correlative Studies Peer-reviewed conference presentation (Presenter) American Society of Hematology; New Orleans, LA

INTERNATIONAL

Jun 07, 2023	SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Peer-reviewed conference presentation (Presenter) EHA; Frankfurt, Germany
May 11, 2023	How i treat Acute Myeloid Leukemia Peer-reviewed conference presentation (Presenter) HIKMA; Türkiye
May 05, 2023	Management of Lower-Risk MDS Peer-reviewed conference presentation (Presenter) SOHO; Türkiye

Mar 29, 2023	Venetoclax based therapy & predictors of response in newly diagnosed AML patients Peer-reviewed conference presentation (Presenter) DAVA Oncology; Whistler, Canada
Mar 29, 2023	Cladribine + venetoclax and other novel strategies for induction of early-stage AML Peer-reviewed conference presentation (Presenter) DAVA Oncology; Whistler, Canada
Oct 23, 2022	Non-Intensive Treatment of Elderly/Unfit Patients with AML Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology; Rome, Italy
Jun 10, 2022	A Phase Ib Trial of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL) Invited talk/seminar (Presenter) EHA 2022 Hybrid Congress; Vienna, Austria
May 14, 2021	New Biological Insights ad Novel Drugs in AML Peer-reviewed conference presentation (Presenter) Section of Hematology & Romagna Metropolitan Transplant Network - Hospital of Ravenna; Ravenna, Italy
Sep 22, 2020	Treating Oldeer Patients with Newly Diagnosed AML 2nd Itallian Conference Invited talk/seminar (Presenter) Italian Society of Hematologic ONcologySOHO; Rome, Italy
Aug 07, 2020	ASCO Direct Highlights in Leukemia Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); San Juan, Puerto Rico
Jul 18, 2020	ASCO Direct Highlights in Leukemia Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Denver, CO
Jun 27, 2020	ASCO Direct Highlights in Leukemia Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Boston, MA
May 07, 2020	MDACC Experience of T-Prolymphocytic Leukemia Postponed Invited talk/seminar (Presenter) International T-PLL Consortium Meeting; Vienna, Austria
Sep 25, 2019	How I Treat Elderly AML Peer-reviewed conference presentation (Presenter) Italian Society of Hematologic Oncology; Rome, Italy
Sep 25, 2019	Approach To the Treatment of Older Patients with AML Peer-reviewed conference presentation (Presenter) Italian Society of Hematologic Oncology (SOHO); Rome, Italy
Jun 2019	EDUCATION SESSION: Less is More in the Treatment of Older Patients with AML Invited talk/seminar (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
May 31, 2019	Leveraging Evidence to Optimize Applications of Novel Therapies in AML - Personalizing Therapy in AML Satellite Education Session Invited talk/seminar (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL

Apr 26, 2019	State of the Art in AML Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology - Columbia; Bogota, Colombia
Apr 26, 2019	What's the Place of New Agents in AML? Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology - Columbia; Bogota, Colombia
Apr 26, 2019	AML in Older Patients: Something is Changing Peer-reviewed conference presentation (Presenter) Society of Hematologic Oncology - Columbia; Bogota, Colombia
Apr 11, 2019	Management of Lower Risk MDS Hikma Cancer Network Invited talk/seminar (Presenter) Annual MENA Conference; Lisbon, Portugal
Apr 11, 2019	Management of Older Patients with Newly Diagnosed AML Hikma Cancer Network Peer-reviewed conference presentation (Presenter) Annual MENA Conference; Lisbon, Portugal
Jun 18, 2018	Phase IB Study of the CXCR4 antogonist BL8040 combined with immunosuppressive Therapy in patients with Aplastic Anemia Peer-reviewed conference presentation (Presenter) European Hematology Association (EHA); Stockholm, SE Sweden
Jun 02, 2018	Nivolumab Maintenance in high-risk Acute Myeloid Leukemia (AML) Patients Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Apr 09, 2018	3+7 is No Longer the Standard of Care Hikma Cancer Network Peer-reviewed conference presentation (Presenter) 2nd Annual MENA Cancer Conference; Dead Sea, Jordan
Apr 09, 2018	Treating Patients with Acute Myeloid Leukemia Hikma Cancer Network Invited talk/seminar (Presenter) 2nd Annual MENA Cancer Conference; Dead Sea, Jordan Jordan
Apr 09, 2018	Novel Agents in AML Hikma Cancer Network Peer-reviewed conference presentation (Presenter) 2nd Annual MENA Cancer Conference; Dead Sea, Jordan
Mar 19, 2018	Novel Agents in AML Invited talk/seminar (Presenter) EBMT Annual Meeting; Lisbon, Portugal
Mar 18, 2018	Treatment of Older Patients with AML Invited talk/seminar (Presenter) EBMT Annual Meeting; Lisbon, Portugal
Jun 30, 2017	Treatment of Myelodyplastic Syndromes Invited talk/seminar (Presenter) The Albert Einstein Research and Education Institute - XI Board Review in Hematology and Transfusion Medicine; Sao Paulo, Brazil
Jun 29, 2017	AcuteMyeloid Leukemia in the WHO 2016 Classification: What is going to change? What will be the therapeutic impact? Invited talk/seminar (Presenter)

	The Albert Einstein Research and Education Institute --XI Board Review in Hematology and Transfusion Medicine; Sao Paulo, Brazil
Jun 23, 2017	Lenalidomide Maintenance in Patients with High Risk Acute Myeloid Leukemia Peer-reviewed conference presentation (Presenter) EHA - 22nd Congress of the European Hematology Association; Madrid, Spain
Jun 06, 2017	Session Chair: Leukemia, MDS, Allogeneic SCT Invited talk/seminar (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Jun 02, 2017	Outcomes with Lower Intensity Therapy in TP53-Mutated Acute Myeloid Leukemia (AML) Peer-reviewed conference presentation (Presenter) American Society of Clinical Oncology (ASCO); Chicago, IL
Sep 30, 2016	Hypomethylating Agents in AML: Past, Present, and Future Invited talk/seminar (Presenter) Spanish Society of Hematology and Therapy; Madrid, Spain
Aug 30, 2013	Is 7+3 still the induction regimen for Acute Myeloid Leukemia patients? Invited talk/seminar (Presenter) Asia Pacific Hematology Consortium AUBH2013; Bangkok, Thailand
Aug 30, 2013	Drug of Choice for Chronic Myelogenous Leukemia? Invited talk/seminar (Presenter) Asia Pacific Hematology Consortium AUBH2013; Bangkok, Thailand
Aug 30, 2013	High Risk MDS: Upfront Transplant? Invited talk/seminar (Presenter) Asia Pacific Hematology Consortium AUBH2013; Bangkok, Thailand
May 18, 2013	Treatment Sequence for AML Patients Invited talk/seminar (Presenter) 4th Annual Regional Hematology – Oncology Symposium; Cartagena, Colombia
May 18, 2013	New Therapy Options for Management of AML Patients Invited talk/seminar (Presenter) 4th Annual Regional Hematology – Oncology Symposium; Cartagena, Colombia
Sep 22, 2012	MDS: Current Thinking of the Disease, Diagnosis and Treatment (Lower-Risk) Invited talk/seminar (Presenter) Aplastic Anemia & MDS International Foundation; Dallas, TX
Sep 22, 2012	Advances in MDS Treatment: What's on the Horizon Invited talk/seminar (Presenter) Aplastic Anemia & MDS International Foundation; Dallas, TX
Nov 12, 2010	Supportive therapy in MDS Invited talk/seminar (Presenter) Congress of the Columbian Association of Hematology & Oncology, Armenia; Bogota, Colombia
Nov 12, 2010	Management of AML after MDS in non - transplant candidates Invited talk/seminar (Presenter) Congress of the Columbian Association of Hematology & Oncology, Armenia; Bogota, Colombia

PUBLICATIONS

JOURNAL ARTICLES - ORIGINAL RESEARCH

1. Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, **Kadia, TM**, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR,

Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal. 2025 Dec 01; 15(1) PMID: 40164584 PMCID: PMC11958769.

2. Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, **Kadia, TM**, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal. 2025 Dec 01; 15(1) PMID: 40089460 PMCID: PMC11910597.

3. Willekens, C, Bazinet, A, Chraibi, S, Bataller Torralba, A, Decroocq, J, Arani, N, Carpentier, B, Rausch, C, Lebon, D, Maiti, A, Gauthier, N, Short, NJ, Bonnet, S, Sasaki, K, Khalife-Hachem, S, Swaminathan, M, Micol, JB, Pasquier, F, Marzac, C, Roos-Weil, D, Pascal, L, Daver, N, **Kadia, TM**, Bouscary, D, Ravandi-Kashani, F, Pages, A, Kantarjian, HM, De Botton, S, DiNardo, C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood cancer journal. 2025 Dec 01; 15(1) PMID: 40246832 PMCID: PMC12006504.

4. DiNardo, C, Jen, WY, Montalban Bravo, G, Wang, X, Loghavi, S, Lavu, S, Short, NJ, Chien, KS, Issa, GC, Pemmaraju, N, Yilmaz, M, Andreeff, M, Borthakur, G, **Kadia, TM**, Daver, N, Garcia-Manero, G, Mill, CP, Su, X, Fiskus, WC, Bhalla, K. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia. 2025 Nov 01; 2(4) PMID: 40979071 PMCID: PMC12447878.

5. Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, **Kadia, TM**, DiNardo, C, Daver, N, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia. 2025 Sep 01; 39(9):2256-2265. PMID: 40691503 https://doi.org/10.1038/s41375-025-02711-6.

6. DiNardo, C, Marvin-Peek, J, Loghavi, S, Takahashi, K, Issa, GC, Jen, WY, Daver, N, Reville, PK, Short, NJ, Sasaki, K, Mullin, JK, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Abbas, HA, Hammond, DE, Haddad, FG, Bravo, GM, Chien, KS, Yilmaz, M, Kornblau, SM, Jabbour, EJ, Ravandi-Kashani, F, **Kadia, TM**, Garcia-Manero, G, Konopleva, M, Kantarjian, HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology. 2025 Aug 20; 43(24):2692-2699. PMID: 40513054 PMCID: PMC12377212.

7. Senapati, J, Kantarjian, HM, **Kadia, TM**, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer. 2025 Aug 15; 131(16) PMID: 40772501 PMCID: PMC12329781.

8. Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, **Kadia, TM**, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer. 2025 Aug 15; 131(16) PMID: 40782343 PMCID: PMC12335293.

9. Tefferi, A, Fathima, S, Abdelmagid, M, Alsugair, AA, Aperna, F, Rezasoltani, M, Yousuf, M, Natu, A, Csizmar, C, Gurney, M, Lasho, T, Finke, C, Kangal-Shamanna, R, Hammond, DE, Chien, KS, Bazinet, A, DiNardo, C, **Kadia, TM**, Mangaonkar, AA, Daver, N, Pardanani, A, Borthakur, G, Zepeda-Mendoza, CJ, Reichard, KK, He, R, Loghavi, S, Passamonti, F, Ravandi-Kashani, F, Sasaki, K, Larson, DR, Garcia-Manero, G, Onida, F, Gangat, N, Montalban Bravo, G, Patnaik, MM. BLAST. Blood. 2025 Aug 14; 146(7):874-886. PMID: 40332442 https://doi.org/10.1182/blood.2024027170.

10. Berkman, AM, Andersen, C, Puthenpura, V, Short, NJ, Merriman, K, Swaminathan, M, Cuglievan, B, McCall, DC, DiNardo, C, Nunez, CA, Jain, N, **Kadia, TM**, Issa, GC, Gibson, A, Garcia, MB, Andrew Livingston, J, Parsons, SK, Hildebrandt, MA, Roth, M. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum. 2025 Aug 01; 9(4) PMID: 40579211 PMCID: PMC12231595.

11. Csizmar, C, Natu, A, Gurney, M, Fathima, S, Alsugair, AA, Kanagal Shamanna, R, Loghavi, S, Bazinet, A, Chien, KS, Hammond, DE, DiNardo, C, **Kadia, TM**, Ravandi-Kashani, F, Pemmaraju, N, Sasaki, K, Lasho, T, Finke, C, Al-Kali, A, Alkhateeb, HB, Begna, K, Gangat, N, Hefazi Torghabeh, M, Matin, A, Mangaonkar, AA, Saliba, AN, Tefferi, A, Garcia-Manero, G, Kantarjian, HM, Komrokji, RS, Xie, Z, Ali, NA, Sallman, D, Padron, E, Montalban Bravo, G, Patnaik, MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia. 2025 Aug 01; 39(8):2030-2034. PMID: 40555734 https://doi.org/10.1038/s41375-025-02648-w.

12. **Kadia, TM**, Jen, WY, Bataller Torralba, A, Bazinet, A, Borthakur, G, Jabbour, EJ, Qiao, W, Short, NJ, Takahashi, K, Issa, GC, DiNardo, C, Montalban Bravo, G, Pemmaraju, N, Tran, A, Bharathi, V, Loghavi, S, Alousi, AM, Popat, UR, Daver, N, Ravandi-Kashani, F, Kantarjian, HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. American journal of hematology. 2025 Aug 01; 100(8):1365-1373. PMID: 40401707 https://doi.org/10.1002/ajh.27723.

13. Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, **Kadia, TM**, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia. 2025 Jul 01; 39(7):1640-1649. PMID: 40346311 https://doi.org/10.1038/s41375-025-02634-2.

14. Reville, PK, Wang, B, Marvin-Peek, J, Yuan, B, Kuo, YA, Garza, AI, Root, J, Qiao, W, Arruda, A, Veletic, I, Liu, Y, Short, NJ, DiNardo, C, **Kadia, TM**, Daver, N, Lorenzi, PL, Sasaki, K, Kornblau, SM, Minden, MD, Ravandi-Kashani, F, Kantarjian, HM, Abbas, HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood. 2025 Jun 19; 145(25):3015-3029. PMID: 40179376 PMCID: PMC12226760.

15. Daver, N, Senapati, J, Kantarjian, HM, Wang, B, Reville, PK, Loghavi, S, Yilmaz, M, DiNardo, C, **Kadia, TM**, Yassouf, MY, Maiti, A, Arora, S, Montalban Bravo, G, Tang, G, Borthakur, G, Sasaki, K, Pemmaraju, N, Alvarez, J, Nogueras Gonzalez, G, Ning, J, Issa, GC, Konopleva, M, Andreeff, M, Ravandi-Kashani, F, Garcia-Manero, G, Abbas, HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 2025 Jun 15; 31(12):2386-2398. PMID: 40198272 PMCID: PMC12165814.

16. Lontos, K, Saliba, RM, Kanagal Shamanna, R, Ozcan, G, Ramdial, JL, Chen, GL, **Kadia, TM**, Short, NJ, Daver, N, Kantarjian, HM, Marin, D, Kebriaei, P, Popat, UR, Champlin, RE, Shpall, E, Oran, B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Advances. 2025 Jun 10; 9(11):2845-2854. PMID: 39853269 PMCID: PMC12198588.

17. Senapati, J, Loghavi, S, Garcia-Manero, G, Tang, G, **Kadia, TM**, Short, NJ, Abbas, HA, Arani, N, DiNardo, C, Borthakur, G, Pemmaraju, N, Oran, B, Shpall, E, Popat, UR, Champlin, RE, Pierce, S, Arora, S, Issa, GC, Yilmaz, M, Patel, KP, Takahashi, K, Montalban Bravo, G, Hammond, DE, Haddad, FG, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica. 2025 Jun 01; 110(6):1304-1315. PMID: 39665206 PMCID: PMC12130771.

18. Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, **Kadia, TM**, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research. 2025 Jun 01; 153 PMID: 40252309 https://doi.org/10.1016/j.leukres.2025.107692.

19. Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, **Kadia, TM**, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology. 2025 May 01; 100(5):758-769. PMID: 39921561 https://doi.org/10.1002/ajh.27628.

20. Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, **Kadia, TM**. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer. 2025 Apr 15; 131(8) PMID: 40193193 https://doi.org/10.1002/cncr.35840.

21. DiNardo, C, Jen, WY, Takahashi, K, **Kadia, TM**, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia. 2025 Apr 01; 39(4):854-863. PMID: 40000842 PMCID: PMC11978487.

22. Bazinet, A, Bataller Torralba, A, **Kadia, TM**, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer. 2025 Mar 15; 131(6) PMID: 40097915 https://doi.org/10.1002/cncr.35813.

23. Kugler, E, Kantarjian, H, Jabbour, EJ, Khaire, N, Short, NJ, **Kadia, TM**, Haddad, FG, Sasaki, K, Kanagal Shamanna, R, Garris, R, Ravandi-Kashani, F, Jain, N. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2025 Mar 01; 131(5) PMID: 39980368 https://doi.org/10.1002/cncr.35773.

24. Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, **Kadia, TM**, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology. 2025 Mar 01; 100(3):402-407. PMID: 39757533 https://doi.org/10.1002/ajh.27576.

25. Jen, WY, Sasaki, K, Ravandi-Kashani, F, **Kadia, TM**, Wang, S, Wang, W, Loghavi, S, Daver, N, DiNardo, C, Issa, GC, Abbas, HA, Nasnas, C, Bataller Torralba, A, Urrutia, S, Karrar, OS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Advances. 2025 Feb 25; 9(4):783-792. PMID: 39631072 PMCID: PMC11869955.

26. Gangat, N, Elbeih, A, Ghosoun, N, McCullough, K, Aperna, F, Johnson, IM, Abdelmagid, M, Al-Kali, A, Alkhateeb, HB, Begna, K, Elliott, MA, Mangaonkar, AA, Matin, A, Saliba, AN, Hefazi Torghabeh, M, Litzow, M, Hogan, WJ, Shah, MV, Patnaik, MM, Pardanani, A, Badar, T, Murthy, H, Foran, J, Palmer, J, Sproat, L, Khera, N, Arana Yi, C, Yates, S, Sneider, A, Dworkin, E, Patel, A, Bazinet, A, Senapati, J, Bataller Torralba, A, DiNardo, C, **Kadia, TM**, Tefferi, A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. American journal of hematology. 2025 Feb 01; 100(2):260-271. PMID: 39671248 PMCID: PMC11705209.

27. Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, **Kadia, TM**. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology. 2025 Feb 01; 100(2):249-259. PMID: 39718824 https://doi.org/10.1002/ajh.27561.

28. Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, **Kadia, TM**, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025 Jan 01; 131(1) PMID: 39584789 PMCID: PMC11695139.

29. Kantarjian, H, Short, NJ, Haddad, FG, Jain, N, Huang, X, Montalban-Bravo, G, Kanagal-Shamanna, R, **Kadia, TM**, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Garris, R, Nasnas, C, Nasr, L, Ravandi, F, Jabbour, EJ. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology. 2024 Dec 20; 42(36):4246-4251. PMID: 39028925 https://doi.org/10.1200/JCO.24.00272.

30. Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, **Kadia, TM**, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology. 2024 Dec 01; 17(1) PMID: 39548557 PMCID: PMC11568598.

31. Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, N, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, **Kadia, TM**. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice. 2024 Dec 01; 20(12):1637-1644. PMID: 39013130 https://doi.org/10.1200/OP.24.00027.

32. McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, **Kadia, TM**. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers. 2024 Nov 01; 16(22) PMID: 39594839 PMCID: PMC11592422.

33. Yeh, JC, Pasvolsky, O, Saliba, RM, Figgins, B, Wang, C, Fang, Z, Ahmed, S, Yilmaz, M, Daver, N, Ravandi, F, DiNardo, CD, Short, NJ, **Kadia, TM**, Al-Atrash, G, Daher, M, Costa, DM, Popat, U, Champlin, R, Shpall, EJ, Oran, B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 2024 Nov 01; 24(11):e819-e826. PMID: 39183099 https://doi.org/10.1016/j.clml.2024.07.001.

34. Desai, PM, Lonial, S, Cashen, A, Kamdar, M, Flinn, IW, O'Brien, S, Garcia, JS, Korde, N, Moslehi, JJ, Wey, M, Cheung, P, Sharma, S, Olabode, D, Chen, H, Syed, FA, Liu, M, Saeh, J, Andrade-Campos, M, **Kadia, TM**, Blachly, JS. A Phase 1 First-in-Human Study

of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 2024 Nov 01; 30(21):4844-4855. PMID: 39167622 PMCID: PMC11528199.

35. Bataller Torralba, A, Kantarjian, H, Bazinet, A, **Kadia, TM**, Daver, N, DiNardo, CD, Borthakur, G, Loghavi, S, Patel, K, Tang, G, Sasaki, K, Short, NJ, Yilmaz, M, Issa, GC, Alvarado, Y, Montalban-Bravo, G, Maiti, A, Abbas, HA, Takahashi, K, Pierce, S, Jabbour, EJ, Garcia-Manero, G, Ravandi, F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024 Nov 01; 109(11):3543-3556. PMID: 38695144 PMCID: PMC11532689.

36. Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, **Kadia, TM**, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 2024 Oct 15; 130(20):3452-3462. PMID: 38896064 https://doi.org/10.1002/cncr.35433.

37. Haddad, FG, Sasaki, K, Nasr, L, Short, NJ, **Kadia, TM**, Dellasala, S, Cortes, JE, Nicolini, F, Issa, GC, Jabbour, EJ, Kantarjian, HM. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352. PMID: 38804723 https://doi.org/10.1002/cncr.35384.

38. Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, **Kadia, TM**. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343. PMID: 38809547 PMCID: PMC12132108.

39. DiNardo, C, Verma, D, Baran, N, Bhagat, TD, Skwarska, A, Lodi, A, Saxena, K, Cai, T, Su, X, Guerra, VA, Poigaialwar, G, Kuruvilla, VM, Konoplev, S, Gordon-Mitchell, S, Pradhan, K, Alluri, S, Hackman, GL, Chaudhry, S, Collins, M, Sweeney, SR, Busquets, J, Rathore, AS, Deng, Q, Green, M, Grant, S, Demo, SD, Choudhary, GS, Sahu, S, Agarwal, B, Spodek, M, Thiruthuvanathan, V, Will, B, Steidl, U, Tippett, G, Burger, JA, Borthakur, G, Jabbour, EJ, Pemmaraju, N, **Kadia, TM**, Kornblau, SM, Daver, N, Naqvi, K, Short, NJ, Garcia-Manero, G, Tiziani, S, Verma, A, Konopleva, M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes. Nature Cancer. 2024 Oct 01; 5(10):1515-1533. PMID: 39300320 https://doi.org/10.1038/s43018-024-00811-3.

40. Loghavi, S, Wei, Q, Ravandi-Kashani, F, Quesada, AE, Routbort, MJ, Hu, S, Toruner, GA, Wang, S, Wang, W, Miranda, R, Li, S, Xu, J, DiNardo, C, Daver, N, **Kadia, TM**, Issa, GC, Kantarjian, HM, Medeiros, LJ, Tang, G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. American journal of hematology. 2024 Oct 01; 99(10):1959-1968. PMID: 39016111 https://doi.org/10.1002/ajh.27435.

41. Jabbour, EJ, Haddad, FG, Sasaki, K, Carter, BZ, Alvarado, Y, Nasnas, C, Nasr, L, Masarova, L, Daver, N, Pemmaraju, N, Short, NJ, Skinner, J, **Kadia, TM**, Borthakur, G, Garcia-Manero, G, Ravandi-Kashani, F, Issa, GC, Andreeff, M, Kantarjian, HM. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659. PMID: 38591430 https://doi.org/10.1002/cncr.35317.

42. Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, **Kadia, TM**, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances. 2024 Jun 11; 8(11):2695-2706. PMID: 38513082 PMCID: PMC11170163.

43. Sasaki, K, Ravandi-Kashani, F, **Kadia, TM**, DiNardo, C, Yilmaz, M, Short, NJ, Jabbour, EJ, Patel, KP, Loghavi, S, Pierce, S, Borthakur, G, Kantarjian, HM. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 2024 Jun 01; 24(6):375-381. PMID: 38431521 PMCID: PMC11809075.

44. Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, N, Pemmaraju, N, Jabbour, EJ, Takahashi, K, **Kadia, TM**, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia. 2024 Jun 01; 1(2) https://doi.org/10.1016/j.bneo.2024.100008.

45. Jen, WY, Sasaki, K, Loghavi, S, Wang, S, Qiao, W, Borthakur, G, Ravandi-Kashani, F, **Kadia, TM**, Issa, GC, Short, NJ, Yilmaz, M, Daver, N, DiNardo, C. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. British Journal of Haematology. 2024 Jun 01; 204(6):2259-2263. PMID: 38603594 PMCID: PMC11770636.

46. Fiskus, WC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Mill, CP, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, **Kadia, TM**, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Reville, PK, Wang, J, Loghavi, S, Sen, R, Ruan, X, Su, X, Flores, L, DiNardo, C, Bhalla, K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024 May 16; 143(20):2059-2072. PMID: 38437498 PMCID: PMC11830987.

47. Khouri, IF, Alzahrani, K, Kantarjian, HM, Milton, D, Gulbis, A, Sasaki, K, Jain, N, Short, NJ, **Kadia, TM**, Daher, M, Rafei, H, Im, JS, Marin, D, Olson, AL, Popat, UR, Qazilbash, MH, Ramdial, JL, Rondon, G, Srour, S, Kebriaei, P, Shpall, E, Champlin, RE, Jabbour, EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology. 2024 May 01; 99(5):836-843. PMID: 38400519 PMCID: PMC11001510.

48. Short, NJ, Daver, N, DiNardo, C, **Kadia, TM**, Nasr, L, Macaron, W, Yilmaz, M, Borthakur, G, Montalban Bravo, G, Garcia-Manero, G, Issa, GC, Chien, KS, Jabbour, EJ, Nasnas, C, Huang, X, Qiao, W, Matthews, JA, Stojanik, CJ, Patel, KP, Abramova, R, Thankachan, J, Konopleva, M, Kantarjian, HM, Ravandi-Kashani, F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML. Journal of Clinical Oncology. 2024 May 01; 42(13):1499-1508. PMID: 38277619 PMCID: PMC11095865.

49. Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, **Kadia, TM**, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology. 2024 Apr 01; 11(4):e276-e286. PMID: 38452788 https://doi.org/10.1016/S2352-3026(24)00033-4.

50. Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, **Kadia, TM**, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research. 2024 Apr 01; 30(7):1319-1326. PMID: 38300723 PMCID: PMC11815990.

51. Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, **Kadia, TM**. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology. 2024 Apr 01; 11(4):e287-e298. PMID: 38548404 https://doi.org/10.1016/S2352-3026(24)00034-6.

52. Narayan, R, Piérola, AA, Donnellan, W, Yordi, AM, Abdul-Hay, M, Platzbecker, U, Subklewe, M, **Kadia, TM**, Alonso-Dominguez, J, McCloskey, J, Bradford, K, Curtis, M, Daskalakis, N, Guttke, C, Safer, K, Hiebert, B, Murphy, J, Li, X, Duchin, K, Esteban, D. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clinical and translational science. 2024 Mar 01; 17(3) PMID: 38494922 PMCID: PMC10945216.

53. Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, **Kadia, TM**, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology. 2024 Mar 01; 11(3):e186-e195. PMID: 38316133 https://doi.org/10.1016/S2352-3026(23)00367-8.

54. Birdwell, C, Fiskus, WC, **Kadia, TM**, Mill, CP, Sasaki, K, Daver, N, DiNardo, C, Pemmaraju, N, Borthakur, G, Davis, JA, Das, K, Sharma, S, Horrigan, SK, Ruan, X, Su, X, Khoury, J, Kantarjian, HM, Bhalla, K. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar 01; 38(3):545-556. PMID: 38086946 PMCID: PMC12122007.

55. Montalban Bravo, G, Jabbour, EJ, Borthakur, G, **Kadia, TM**, Ravandi-Kashani, F, Chien, KS, Pemmaraju, N, Hammond, DE, Dong, XQ, Huang, X, Schneider, H, John, RB, Kanagal-Shamana, R, Loghavi, S, Kantarjian, HM, Garcia-Manero, G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology. 2024 Mar 01; 204(3):898-909. PMID: 37946611 https://doi.org/10.1111/bjh.19193.

56. Bataller, A, Bazinet, A, DiNardo, C, Maiti, A, Borthakur, G, Daver, N, Short, NJ, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Takahashi, K, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, **Kadia, TM**. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances. 2024 Feb 27; 8(4):927-935. PMID: 38113472 PMCID: PMC10877112.

57. Jabbour, EJ, Haddad, FG, Short, NJ, Senapati, J, Jain, N, Sasaki, K, Jorgensen, JL, Wang, SA, Alvarado, Y, Wang, X, DiNardo, C, Masarova, L, **Kadia, TM**, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421. PMID: 37879077 https://doi.org/10.1182/blood.2023022330.

58. Jen, WY, Sasaki, K, Rausch, CR, DiNardo, C, **Kadia, TM**, Yilmaz, M, Borthakur, G, Alvarado, Y, McCue, D, McCue, D, Kantarjian, HM, Ravandi-Kashani, F. Acute kidney injury in acute promyelocytic leukemia. Leukemia and Lymphoma. 2024 Jan 01; 65(3):378-382. PMID: 38054837 https://doi.org/10.1080/10428194.2023.2290467.

59. Sasaki, K, Ravandi-Kashani, F, DiNardo, C, Welch, MA, **Kadia, TM**, Kantarjian, HM. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 2023 Dec 01; 23(12):905-910. PMID: 37730483 https://doi.org/10.1016/j.clml.2023.08.016.

60. Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, **Kadia TM**, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood. E-pub ahead of print: 2023 Nov 09; 142(19):1647-1657. PMID: 37441846 https://doi.org/10.1182/blood.2023020649.

61. Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, **Kadia, TM**, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology. 2023 Nov 01; 98(11):1780-1790. PMID: 37665752 PMCID: PMC11770637.

62. Senapati, J, Fiskus, WC, Daver, N, Wilson, NR, Ravandi-Kashani, F, Garcia-Manero, G, **Kadia, TM**, DiNardo, C, Jabbour, EJ, Burger, JA, Short, NJ, Alvarado, Y, Jain, N, Masarova, L, Issa, GC, Qiao, W, Khoury, J, Pierce, SR, Miller, D, Sasaki, K, Konopleva, M, Bhalla, K, Borthakur, G, Pemmaraju, N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research. 2023 Nov 01; 29(21):4352-4360. PMID: 37585491 https://doi.org/10.1158/1078-0432.CCR-23-1429.

63. **Kadia, TM**, Ravandi-Kashani, F, Molica, M, Bataller, A, Borthakur, G, Daver, N, Jabbour, EJ, DiNardo, C, Pemmaraju, N, Jain, N, Ferrajoli, A, Ylimaz, M, Bose, P, Tidwell, R, Marx, KR, Rausch, CR, Kanagal Shamanna, R, Wang, S, Islam, R, Champlin, RE, Shpall, E, Konopleva, M, Garcia-Manero, G, Kantarjian, HM. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American journal of hematology. 2023 Nov 01; 98(11):1711-1720. PMID: 37635400 PMCID: PMC11756386.

64. Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, **Kadia, TM**, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology. 2023 Nov 01; 203(4):581-592. PMID: 37608562 https://doi.org/10.1111/bjh.19060.

65. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, **Kadia TM**, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. E-pub ahead of print: 2023 Oct 01; 98(10):E281-E284. PMID: 37515433 https://doi.org/10.1002/ajh.27043.

66. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. E-pub ahead of print: 2023 Oct 01; 98(10):1619-1626. PMID: 37485584 PMCID: PMC11526380.

67. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, **Kadia TM**. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. E-pub ahead of print: 2023 Sep 01; 108(9):2331-2342. PMID: 36951163 PMCID: PMC10483357.

68. Fang H, Beird HC, Wang SA, Ibrahim AF, Tang Z, Tang G, You MJ, Hu S, Xu J, Li S, Yin CC, El Hussein S, Le N, Futreal PA, Bueso-Ramos C, Thakral B, **Kadia TM**, Thornton R, Little L, Gumbs C, Song X, Medeiros LJ, Wang W. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. Leukemia. E-pub ahead of print: 2023 Sep 01; 37(9):1919-1921. PMID: 37443196 https://doi.org/10.1038/s41375-023-01956-3.

69. Senapati J, **Kadia TM**, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica. E-pub ahead of print: 2023 Sep 01; 108(9):2289-2304. PMID: 37139599 PMCID: PMC10483353.

70. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, **Kadia TM**, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv. 2023 Jul 25; 7(14):3573-3581. PMID: 37104058 PMCID: PMC10368841.

71. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv. 2023 Jul 11; 7(13):3284-3296. PMID: 36884300 PMCID: PMC10336257.

72. Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, **Kadia TM**, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023 Jul 05; 4(4):276-293. PMID: 37102976 PMCID: PMC10320628.

73. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, **Kadia TM**, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 Jul; 37(7):1444-1453. PMID: 37138019 PMCID: PMC11913176.

74. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, **Kadia TM**, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer. 2023 Jun 15; 129(12):1866-1872. PMID: 36882573 https://doi.org/10.1002/cncr.34725.

75. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, **Kadia TM**, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 Jun 15; 129(12):1856-1865. PMID: 36892949 PMCID: PMC12013980.

76. DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 Jun 13; 7(11):2378-2387. PMID: 35973199 PMCID: PMC10220255.

77. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, **Kadia TM**, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 Jun; 37(6):1336-1348. PMID: 36977823 PMCID: PMC10244173.

78. Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 Jun; 98(6):E142-E144. PMID: 36877196.

79. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, **Kadia TM**, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444. PMID: 37187201 PMCID: PMC11840755.

80. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv. 2023 May 23; 7(10):1958-1966. PMID: 36287248 PMCID: PMC10189379.

81. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 May 02; 16(1):44. PMID: 37131217 PMCID: PMC10155451.

82. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 May; 7:e2200707. PMID: 37196217 PMCID: PMC10309573.

83. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related

myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 May; 201(3):e25-e29. PMID: 36951293 https://doi.org/10.1111/bjh.18766.

84. Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, **Kadia TM**, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 Apr 13; 13(1):53. PMID: 37055414 PMCID: PMC10102188.

85. Sasaki K, Ravandi F, **Kadia TM**, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 Apr 01; 129(7):1017-1029. PMID: 36715486 PMCID: PMC11931673.

86. Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res. 2023 Apr; 127:107044. PMID: 36801700 https://doi.org/10.1016/j.leukres.2023.107044.

87. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, **Kadia TM**, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 Apr; 98(4):658-665. PMID: 36683287 PMCID: PMC11576052.

88. Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol. 2023 Apr; 98(4):E91-E94. PMID: 36661399 https://doi.org/10.1002/ajh.26858.

89. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, **Kadia TM**, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 Mar 28; 7(6):933-942. PMID: 36322818 PMCID: PMC10027507.

90. Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel). 2023 Mar 26; 15(7) PMID: 37046645 PMCID: PMC10093646.

91. Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, **Kadia TM**. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv. 2023 Mar 14; 7(5):828-831. PMID: 35405739 PMCID: PMC9996355.

92. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 Mar; 98(3):E53-E56. PMID: 36565294 https://doi.org/10.1002/ajh.26811.

93. Bazinet A, Darbaniyan F, **Kadia TM**, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 Feb 15; 129(4):560-568. PMID: 36458426 https://doi.org/10.1002/cncr.34564.

94. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, **Kadia TM**. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 Feb 15; 129(4):580-589. PMID: 36448227 PMCID: PMC12002038.

95. Aminu, M, Daver, N, Godoy, M, Shroff, G, Wu, CC, Torre-Sada, LF, Goizueta, AA, Shannon, VR, Faiz, S, Altan, M, Garcia-Manero, G, Kantarjian, HM, Ravandi-Kashani, F, **Kadia, TM**, Konopleva, M, DiNardo, C, Pierce, S, Naing, A, Kim, ST, Kontoyiannis, DP, Khawaja, F, Chung, C, Wu, J, Sheshadri, A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia. Frontiers in immunology. 2023 Jan 01; 14 PMID: 37841255 PMCID: PMC10570510.

96. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, **Kadia TM**, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e24-e34. PMID: 36402146 https://doi.org/10.1016/S2352-3026(22)00319-2.

97. Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 Jan; 98(1):E11-E14. PMID: 35633516 https://doi.org/10.1002/ajh.26622.

98. Cantu MD, Kanagal-Shamanna R, Wang SA, Kadia T, Bueso-Ramos CE, Patel SS, Geyer JT, Tam W, Madanat Y, Li P, George TI, Nichols MM, Rogers HJ, Liu YC, Aggarwal N, Kurzer JH, Maracaja DLV, Hsi ED, Zaiem F, Babu D, Foucar K, Laczko D, Bagg A, Orazi A, Arber DA, Hasserjian RP, Weinberg OK. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023 Jan; 7:e2200400. PMID: 36689697 https://doi.org/10.1200/PO.22.00400.

99. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 Dec; 97(12):1560-1567. PMID: 36087091 https://doi.org/10.1002/ajh.26724.

100. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma. 2022 Dec; 63(13):3105-3116. PMID: 36089905 PMCID: PMC9772202.

101. Jabbour E, Short NJ, Jain N, Thompson PA, **Kadia TM**, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885. PMID: 36279879 https://doi.org/10.1016/S2352-3026(22)00285-X.

102. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, **Kadia TM**. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606. PMID: 36117258 PMCID: PMC11975417.

103. **Kadia TM**, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 Nov 20; 40(33):JCO2102823. PMID: 35704787 PMCID: PMC9671758.

104. Babakhanlou R, Kadia T, Chien K, Sasaki K, Thompson PA. Aplastic anemia following the severe acute respiratory syndrome coronavirus-2 vaccine. EJHaem. ePub 2022 Nov 04; PMID: 36718353 PMCID: PMC9877786.

105. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434. PMID: 36053747 https://doi.org/10.1002/ajh.26700.

106. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411. PMID: 36054774 https://doi.org/10.1002/ajh.26698.

107. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, **Kadia TM**, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452. PMID: 36054614 https://doi.org/10.1002/ajh.26694.

108. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, **Kadia TM**, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 Nov; 36(11):2729-2733. PMID: 36151141 PMCID: PMC9613474.

109. Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, Kontoyiannis DP. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis. 2022 Oct 29; 75(9):1503-1510. PMID: 35325094 https://doi.org/10.1093/cid/ciac230.

110. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 Oct 20; 140(16):1753-1763. PMID: 35512188 PMCID: PMC9837415.

111. Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, **Kadia TM**. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv. 2022 Oct 11; 6(19):5546-5549. PMID: 35201293 PMCID: PMC9647734.

112. Kim, K, Ong, F, Montalban Bravo, G, Kanagal Shamanna, R, **Kadia, TM**, Jabbour, EJ, Alvarado, Y, Sasaki, K, Dong, XQ, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Chien, KS, Garcia-Manero, G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S310. PMID: 36163955 https://doi.org/10.1016/S2152-2650(22)01407-0.

113. Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, **Kadia, TM**, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S313-S314. PMID: 36163960 https://doi.org/10.1016/S2152-2650(22)01413-6.

114. Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, **Kadia, TM**, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S321. PMID: 36163977 https://doi.org/10.1016/S2152-2650(22)01427-6.

115. Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, **Kadia, TM**, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S319. PMID: 36163972 https://doi.org/10.1016/S2152-2650(22)01424-0.

116. Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, **Kadia, TM**, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S311. PMID: 36163957 https://doi.org/10.1016/S2152-2650(22)01408-2.

117. Abuasab, T, Mohamed, SF, Biostatistics, HH, Biostatistics, XW, Sasaki, K, Yilmaz, M, **Kadia, TM**, DiNardo, C, Daver, N, Pemmaraju, N, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S243. PMID: 36163827 https://doi.org/10.1016/S2152-2650(22)01281-2.

118. Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, **Kadia, TM**, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S240-S241. PMID: 36163821 https://doi.org/10.1016/S2152-2650(22)01276-9.

119. Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, **Kadia, TM**. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S239-S240. PMID: 36163817 https://doi.org/10.1016/S2152-2650(22)01274-5.

120. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. E-pub ahead of print: 2022 Oct 01; 9(10):e756-e765. PMID: 36063832 https://doi.org/10.1016/S2352-3026(22)00216-2.

121. Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, N, Garcia-Manero, G, **Kadia, TM**, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S233-S234. PMID: 36163805 https://doi.org/10.1016/S2152-2650(22)01261-7.

122. Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, **Kadia, TM**, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S237. PMID: 36163813 https://doi.org/10.1016/S2152-2650(22)01268-X.

123. Abuasab, T, Senapati, J, **Kadia, TM**, Ravandi-Kashani, F, DiNardo, C, Pemmaraju, N, Ohanion, M, Alvarado, Y, Kantarjian, HM, Borthakur, G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)– Based Regimen. Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S235-S236. PMID: 36163808 https://doi.org/10.1016/S2152-2650(22)01265-4.

124. Ong, F, **Kadia, TM**, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia. 2022 Oct 01; 22:S258. PMID: 36163855 https://doi.org/10.1016/S2152-2650(22)01309-X.

125. Fang H, Wang SA, Khoury JD, El Hussein S, Kim DH, Tashakori M, Tang Z, Li S, Hu Z, Jelloul FZ, Patel KP, McDonnell TJ, Kadia T, Medeiros LJ, Wang W. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. E-pub ahead of print: 2022 Sep 01; 107(9):2232-2237. PMID: 35511670 PMCID: PMC9425316.

126. Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022 Sep; 36(9):2306-2316. PMID: 35915143 PMCID: PMC9417987.

127. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, **Kadia TM**, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 Sep; 63(9):1-10. PMID: 35442137.

128. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, **Kadia TM**, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97(9):1127-1134. PMID: 35702875 https://doi.org/10.1002/ajh.26630.

129. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141. PMID: 35713551 https://doi.org/10.1002/ajh.26634.

130. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 Aug; 97(8):1035-1043. PMID: 35583199 PMCID: PMC11812953.

131. Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain

inhibitor PLX51107 and azacitidine. Leuk Res. 2022 Aug; 119:106884. PMID: 35691130 https://doi.org/10.1016/j.leukres.2022.106884.

132. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, **Kadia TM**, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 Jul 15; 128(14):2736-2745. PMID: 35452134 PMCID: PMC9232977.

133. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, **Kadia TM**, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 Jul 12; 6(13):4006-4014. PMID: 35533262 PMCID: PMC9278301.

134. Tashakori M, **Kadia TM**, Loghavi S, Daver NG, Kanagal-Shamanna R, Pierce SR, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins C, Jabbour EJ, Medeiros LJ, Bhalla KN, Kantarjian HM, Ravandi F, Khoury JD. TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia. Blood. E-pub ahead of print: 2022 Jul 07; 140(1):58-72. PMID: 35390143 PMCID: PMC9346958.

135. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 Jul; 97(7):865-876. PMID: 35384048 PMCID: PMC11915495.

136. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 Jul; 97(7):856-864. PMID: 35357036 PMCID: PMC11894569.

137. Tashakori M, Wang W, **Kadia TM**, Daver NG, Montalban-Bravo G, Loghavi S, Wang SA, Medeiros LJ, Ravandi F, Khoury JD. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res. 2022 Jul; 118:106860. PMID: 35636055 https://doi.org/10.1016/j.leukres.2022.106860.

138. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, **Kadia TM**. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 Jul; 97(7):885-894. PMID: 35413152 PMCID: PMC12002036.

139. Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, **Kadia TM**, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev. 2022 Jun 01; 31(6):1176-1184. PMID: 35553621 PMCID: PMC9179079.

140. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 Jun 01; 97(6):E201-E204. PMID: 35266566 PMCID: PMC11832082.

141. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 May 24; 6(10):3027-3035. PMID: 35061885 PMCID: PMC9131912.

142. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 May 02; 12(5):77. PMID: 35501304 PMCID: PMC9061716.

143. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, **Kadia TM**. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360. PMID: 35483396 PMCID: PMC9946440.

144. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022 May; 97(5):574-582. PMID: 35150150 PMCID: PMC9303262.

145. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 Apr; 63(4):885-893. PMID: 35225133.

146. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, **Kadia TM**. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 Mar 01; 97(3):329-337. PMID: 34981570 PMCID: PMC8884919.

147. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 Mar; 63(3):1-4. PMID: 34668451 PMCID: PMC11749422.

148. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, **Kadia TM**, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood. 2022 Feb 10; 139(6):907-921. PMID: 34601571 PMCID: PMC8832475.

149. Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2022 Feb 01; 97(2):E62-E67. PMID: 34807470 https://doi.org/10.1002/ajh.26417.

150. Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, **Kadia TM**, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 Jan 31; 12(1):23. PMID: 35102145 PMCID: PMC8803998.

151. Short NJ, Venugopal S, Qiao W, **Kadia TM**, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 Jan 29; 15(1):12. PMID: 35093134 PMCID: PMC8800349.

152. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 Jan 25; 12(1):10. PMID: 35078972 PMCID: PMC8789767.

153. Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, **Kadia TM**, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 Jan 11; 12(1):5. PMID: 35017466 PMCID: PMC8752621.

154. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 Jan 01; 97(1):68-78. PMID: 34716921 PMCID: PMC11809073.

155. Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, **Kadia TM**, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta Haematol. 2022; 145(5):529-536. PMID: 35717939 https://doi.org/10.1159/000525566.

156. **Kadia TM**, Wei AH. Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents? Cancer J. 2022; 28(1):67-72. PMID: 35072376 PMCID: PMC10123925.

157. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 Dec 14; 5(23):5415-5419. PMID: 34525185 PMCID: PMC9153023.

158. McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver N, **Kadia TM**, DiNardo C, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 Dec 14; 5(23):5215-5219. PMID: 34592761 PMCID: PMC9153013.

159. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, **Kadia TM**, Ravandi F, Buyse ME, Chiao JH. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 Dec 01; 127(23):4421-4431. PMID: 34424530 PMCID: PMC9523989.

160. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, **Kadia TM**. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 Dec; 62(14):3402-3410. PMID: 34380367.

161. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 Dec; 35(12):3421-3429. PMID: 34007049 PMCID: PMC11812922.

162. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, **Kadia TM**, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma. 2021 Dec; 62(14):3501-3505. PMID: 34474640.

163. Maiti A, DiNardo CD, Qiao W, **Kadia TM**, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 Nov 15; 127(22):4213-4220. PMID: 34343352 PMCID: PMC8556232.

164. Awada H, Durmaz A, Gurnari C, Kishtagari A, Meggendorfer M, Kerr CM, Kuzmanovic T, Durrani J, Shreve J, Nagata Y, Radivoyevitch T, Advani AS, Ravandi F, Carraway HE, Nazha A, Haferlach C, Saunthararajah Y, Scott J, Visconte V, Kantarjian H, Kadia T, Sekeres MA, Haferlach T, Maciejewski JP. Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. Blood. 2021 Nov 11; 138(19):1885-1895. PMID: 34075412 PMCID: PMC8767789.

165. Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, **Kadia TM**, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood. 2021 Nov 04; 138(18):1733-1739. PMID: 34115096 PMCID: PMC8569418.

166. Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021 Nov 01; Online ahead of print(11):2853-2858. PMID: 33054123 PMCID: PMC8561288.

167. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, **Kadia TM**, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 Nov 01; 96(11):1420-1428. PMID: 34351647 PMCID: PMC9167467.

168. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, **Kadia TM**, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 Nov; 195(3):378-387. PMID: 34340254 https://doi.org/10.1111/bjh.17689.

169. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 Nov; 35(11):3282-3286. PMID: 33833386 PMCID: PMC8550958.

170. Saxena K, Herbrich SM, Pemmaraju N, **Kadia TM**, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 Oct 15; 127(20):3761-3771. PMID: 34171128 https://doi.org/10.1002/cncr.33690.

171. Kim K, Maiti A, Loghavi S, Pourebrahim R, **Kadia TM**, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021 Oct 15; 127(20):3772-3781. PMID: 34255353 PMCID: PMC10462434.

172. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood. 2021 Oct 14; 138(15):1373-1377. PMID: 34098573 https://doi.org/10.1182/blood.2021011817.

173. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 Oct 01; 127(19):3552-3565. PMID: 34161603 PMCID: PMC10015977.

174. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, **Kadia TM**. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 Oct 01; 127(19):3541-3551. PMID: 34182597 PMCID: PMC12132598.

175. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 Sep 29; 11(9):162. PMID: 34588432 PMCID: PMC8481264.

176. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, **Kadia TM**, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 Sep 01; 127(17):3113-3124. PMID: 33914911 https://doi.org/10.1002/cncr.33622.

177. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 Sep 01; 39(25):2768-2778. PMID: 34043428 PMCID: PMC8407653.

178. Fang H, Wang W, **Kadia TM**, El Hussein S, Wang SA, Khoury JD. CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations. Leuk Res. 2021 Sep; 108:106614. PMID: 33990003 https://doi.org/10.1016/j.leukres.2021.106614.

179. Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Sep; 62(9):1-9. PMID: 33830856.

180. Pemmaraju N, Carter BZ, Bose P, Jain N, **Kadia TM**, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 Aug 24; 5(16):3163-3173. PMID: 34424319 PMCID: PMC8405193.

181. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, **Kadia TM**, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 Aug 01; 127(15):2648-2656. PMID: 33793964 PMCID: PMC11731289.

182. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. E-pub ahead of print: 2021 Aug 01; 7(8):1213-1219. PMID: 34110383 PMCID: PMC8193546.

183. **Kadia TM**, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 Aug 01; 96(8):914-924. PMID: 33901324 PMCID: PMC12002039.

184. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, **Kadia TM**, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 Aug 01; 127(15):2641-2647. PMID: 33823073 https://doi.org/10.1002/cncr.33539.

185. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 Aug 01; 106(8):2121-2130. PMID: 33853292 PMCID: PMC8327731.

186. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 Aug 01; 96(8):E275-E279. PMID: 33891709 PMCID: PMC9154045.

187. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 Aug 01; 96(8):1000-1007. PMID: 33991360 PMCID: PMC9096877.

188. **Kadia TM**, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561. PMID: 34329576 PMCID: PMC8884174.

189. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, **Kadia TM**, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 Jul 15; 127(14):2489-2499. PMID: 33793970 PMCID: PMC8249340.

190. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, **Kadia TM**, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 Jul 01; 96(7):E246-E249. PMID: 33811786 https://doi.org/10.1002/ajh.26182.

191. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 Jul 01; 96(7):E229-E232. PMID: 33780038 PMCID: PMC9278812.

192. Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 Jun 15; 14(1):94. PMID: 34130720 PMCID: PMC8204504.

193. Sasaki K, Ravandi F, **Kadia TM**, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021 Jun 15; 127(12):2049-2061. PMID: 33818756 PMCID: PMC11826308.

194. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, **Kadia TM**, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 Jun 15; 127(12):2025-2038. PMID: 33740268 https://doi.org/10.1002/cncr.33469.

195. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, **Kadia TM**. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 Jun 01; 127(11):1894-1900. PMID: 33449377 PMCID: PMC11949113.

196. **Kadia TM**. FLT3 inhibitors in acute myeloid leukemia: increasing options. Clin Adv Hematol Oncol. 2021 Jun; 19(6):352-355. PMID: 34106908.

197. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, **Kadia TM**, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 May 20; 11(5):98. PMID: 34016956 PMCID: PMC8138012.

198. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, **Kadia TM**, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis. E-pub ahead of print: 2021 May 15; 72(10):1755-1763. PMID: 32236406 PMCID: PMC8130026.

199. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, **Kadia TM**, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 May 10; 12(1):2607. PMID: 33972549 PMCID: PMC8110775.

200. Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, **Kadia TM**, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol. E-pub ahead of print: 2021 May 01; 144(3):1-8. PMID: 33238261 https://doi.org/10.1159/000510112.

201. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, **Kadia TM**, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. E-pub ahead of print: 2021 May 01; 96(5):E154-E157. PMID: 33580980 PMCID: PMC8237705.

202. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, **Kadia TM**, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 May; 35(5):1494-1499. PMID: 33846541 https://doi.org/10.1038/s41375-021-01240-2.

203. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 Apr 27; 5(8):2173-2183. PMID: 33885753 PMCID: PMC8095152.

204. Maiti A, DiNardo CD, Wang SA, Jorgensen J, **Kadia TM**, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 Apr 13; 5(7):1876-1883. PMID: 33792630 PMCID: PMC8045494.

205. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, **Kadia TM**. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 Mar 17; 11(3):60. PMID: 33731681 PMCID: PMC7969746.

206. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 Mar 06; 11(3):52. PMID: 33677472 PMCID: PMC7936977.

207. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, **Kadia TM**, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P,

Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 Mar 01; 106(3):894-898. PMID: 32499238 PMCID: PMC7927994.

208. Maiti A, Qiao W, Sasaki K, Ravandi F, **Kadia TM**, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol. 2021 Mar 01; 96(3):282-291. PMID: 33264443 PMCID: PMC8128145.

209. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, **Kadia TM**, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 Mar; 2(2):125-134. PMID: 33681815 PMCID: PMC7935111.

210. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 Mar; 35(3):691-700. PMID: 32561839 https://doi.org/10.1038/s41375-020-0920-z.

211. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 Mar; 192(6):1054-1063. PMID: 33618432 PMCID: PMC8944196.

212. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, **Kadia TM**, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. PMID: 33618754 PMCID: PMC7901199.

213. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, **Kadia TM**, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 Feb 01; 11(2):25. PMID: 33563904 PMCID: PMC7873265.

214. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Am J Hematol. 2021 Feb 01; 96(2):E50-E53. PMID: 33156969 https://doi.org/10.1002/ajh.26044.

215. Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, **Kadia TM**, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol. 2021 Feb; 192(3):667-671. PMID: 33238033 https://doi.org/10.1111/bjh.17258.

216. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 Feb; 127(3):381-390. PMID: 33119202 https://doi.org/10.1002/cncr.33293.

217. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 Jan; 62(1):1-5. PMID: 32955970 PMCID: PMC11648456.

218. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, **Kadia TM**, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD

negativity in patients with relapsed or refractory AML. Blood Adv. 2020 Dec 22; 4(24):6117-6126. PMID: 33351107 PMCID: PMC7757010.

219. Jammal N, Rausch CR, **Kadia TM**, Pemmaraju N. Cell cycle inhibitors for the treatment of acute myeloid leukemia: A review of phase 2 & 3 clinical trials. Expert Opin Emerg Drugs. 2020 Dec; 25(4):1-9. PMID: 33161749.

220. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 Dec; 95(12):E326-E329. PMID: 32886803.

221. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 Dec; 61(13):1-8. PMID: 32755333.

222. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, **Kadia TM**. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 Nov 24; 4(22):5681-5689. PMID: 33211826 PMCID: PMC7686900.

223. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol. 2020 Nov; 95(11):1288-1295. PMID: 32681739.

224. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 Nov; 20(11):e871-e882. PMID: 32792304.

225. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 Nov; 95(11):1296-1303. PMID: 32697348.

226. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, **Kadia TM**, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 Nov; 34(11):2914-2924. PMID: 32546726.

227. Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Nov; 61(11):1-3. PMID: 32654562.

228. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, **Kadia TM**, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 Oct 08; 13(1):132. PMID: 33032648 PMCID: PMC7542942.

229. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, **Kadia TM**, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301 PMCID: PMC7549397.

230. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, **Kadia TM**, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 Sep; 95(9):E225-E228. PMID: 32356320.

231. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-

pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 Sep; 33(9):1678-1689. PMID: 32238878.

232. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, **Kadia TM**, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 Sep; 34(9):2489-2492. PMID: 32099037.

233. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, **Kadia TM**, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. PMID: 32589978.

234. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 Jul; 95(7):734-739. PMID: 32170867.

235. Yilmaz M, Kadia T, Ravandi F. Identifying effective drug combinations for patients with acute myeloid leukemia. Expert Rev Anticancer Ther. ePub 2020 Jun 30; :1-11. PMID: 32552126.

236. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. ePub 2020 Jun 17; PMID: 32557828.

237. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, **Kadia TM**. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 Jun; 95(6):612-622. PMID: 32112433.

238. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, **Kadia TM**, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 May 15; 126(10):2193-2205. PMID: 32125707.

239. Samra B, Richard-Carpentier G, **Kadia TM**, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 May 04; 10(5):47. PMID: 32366832 PMCID: PMC7198507.

240. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 May 04; 10(5):48. PMID: 32366841 PMCID: PMC7198530.

241. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, **Kadia TM**, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 Apr 28; 4(8):1690-1699. PMID: 32330243 PMCID: PMC7189295.

242. Lachowiez CA, Loghavi S, **Kadia TM**, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 Apr 14; 4(7):1311-1320. PMID: 32251497 PMCID: PMC7160266.

243. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, **Kadia TM**, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. ePub 2020 Apr 14; :1-7. PMID: 32289808.

244. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, **Kadia TM**, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 Apr 09; 135(15):1255-1269. PMID: 32068780 PMCID: PMC7146021.

245. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, **Kadia TM**, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 Apr 01; 126(7):1502-1511. PMID: 31999839.

246. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, **Kadia TM**, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 Apr; 126(7):1448-1459. PMID: 31999850.

247. Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, **Kadia TM**. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leuk Lymphoma. 2020 Mar; 61(3):536-545. PMID: 31752577.

248. Rausch CR, Jabbour EJ, Kantarjian HM, **Kadia TM**. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 Mar; 126(6):1152-1160. PMID: 31794095.

249. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, **Kadia TM**, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 Feb 11; 4(3):482-495. PMID: 32027746 PMCID: PMC7013259.

250. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020 Feb; 61(2):1-5. PMID: 31566032.

251. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, **Kadia TM**, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213. PMID: 33585199 PMCID: PMC7878971.

252. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 Dec; 60(13):3172-3180. PMID: 31125272.

253. Molica M, Naqvi K, Cortes JE, Paul S, **Kadia TM**, Breccia M, Kantarjian H, Jabbour EJ. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696. PMID: 31851157.

254. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov; 125(21):3755-3766. PMID: 31310323.

255. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. ePub 2019 Nov; PMID: 31682008.

256. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, **Kadia TM**, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov; 134(Supplement_1):34. PMID: 31724006.

257. Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, DiNardo CD, **Kadia TM**, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K. Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood. 2019 Nov; 134(Supplement_1):17. PMID: 31724013.

258. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian H, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. ePub 2019 Nov; PMID: 31742675.

259. Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Rácil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019 Oct; 37(29):2632-2642. PMID: 31430225.

260. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961 PMCID: PMC6778960.

261. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 Sep; 125(18):3219-3224. PMID: 31150121.

262. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. 2019 Sep; 12(3):161-165. PMID: 28830803.

263. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. Emerging drug profile: CPX-351 (vyxeos) in AML. Leuk Lymphoma. ePub 2019 Sep; :1-10. PMID: 31547736.

264. Swaminathan M, Borthakur G, **Kadia TM**, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 Sep; 60(9):1-7. PMID: 30773968.

265. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 Aug; 125(15):2579-2586. PMID: 30985931 PMCID: PMC6625850.

266. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, **Kadia TM**, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 Jul; 134(1):59-73. PMID: 31023702 PMCID: PMC6609954.

267. Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. ePub 2019 Jul; :1-2. PMID: 31305193.

268. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol. 2019 Jul; 94(7):E188-E190. PMID: 30977182 PMCID: PMC6566858.

269. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, **Kadia TM**, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. ePub 2019 Jun; :1-4. PMID: 31246142.

270. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. ePub 2019 Jun; PMID: 31237017.

271. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, **Kadia TM**, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML. Am J Hematol. 2019 Jun; 94(6):E158-E160. PMID: 30838674 PMCID: PMC6602057.

272. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, **Kadia TM**, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the

transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 Jun; 125(11):1855-1866. PMID: 30811597.

273. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, **Kadia TM**, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 Jun; 33(6):1373-1386. PMID: 30575820.

274. Kantarjian HM, Jabbour EJ, Garcia-Manero G, **Kadia TM**, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 May; 125(10):1665-1673. PMID: 30668890.

275. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 May; 380(22):2095-2103. PMID: 31141631.

276. Boddu PC, **Kadia TM**, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019 Apr; 125(7):1091-1100. PMID: 30521114 PMCID: PMC6561101.

277. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 Mar; 133(10):1011-1019. PMID: 30530801 PMCID: PMC6405333.

278. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. ePub 2019 Mar; PMID: 30861111 PMCID: PMC6742577.

279. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 Mar; 3(6):922-933. PMID: 30902805 PMCID: PMC6436014.

280. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, **Kadia TM**, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar; 3(6):851-861. PMID: 30885996 PMCID: PMC6436011.

281. Maiti A, Naqvi K, **Kadia TM**, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Mar; 19(3):142-148.e1. PMID: 30635233.

282. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019 Mar; 72(3):251-257. PMID: 30467242.

283. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov. 2019 Mar; 9(3):370-383. PMID: 30409776 PMCID: PMC6397669.

284. Swaminathan M, Bannon SA, Routbort M, Naqvi K, **Kadia TM**, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 Feb; 5(1) PMID: 30709875 PMCID: PMC6371746.

285. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients

with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 Jan 03; 12(1):1. PMID: 30606227 PMCID: PMC6318861.

286. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 Jan; 60(1):1-12. PMID: 29741984 PMCID: PMC6226369.

287. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 Jan; 9(2):7. PMID: 30651532 PMCID: PMC6335405.

288. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, **Kadia TM**, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 Jan; 9(2):4. PMID: 30647404 PMCID: PMC6333829.

289. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, **Kadia TM**, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37. PMID: 30545576 PMCID: PMC6563344.

290. Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res. 2019; 11:8817-8828. PMID: 31632141 PMCID: PMC6782026.

291. Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, **Kadia T**, **Brandt M**, Maduike R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 2018 Dec; 32(12):2698-2701. PMID: 29884905.

292. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, **Kadia TM**. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 Nov; 124(21):4192-4201. PMID: 30307606.

293. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, **Kadia T**, **Routbort M**, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 Nov; 93(11):1376-1383. PMID: 30117185.

294. Abaza Y, Cortes J, Ravandi F, **Kadia T**, **Garcia-Manero G**, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. 2018 Nov; 93(11):E357-E360. PMID: 30074261.

295. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, **Kadia T**, **Cleeland C**, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 Nov; 7(11):5457-5469. PMID: 30318751 PMCID: PMC6246941.

296. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, **Kadia TM**, **Borthakur G**, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 Nov; 32(11):2388-2398. PMID: 29769624 PMCID: PMC6192870.

297. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, **Kadia T**, **Cortes J**, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 Oct; 124(20):4044-4055. PMID: 30307611.

298. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, **Kadia TM**, **Borthakur G**, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 Oct; 93(10):1245-1253. PMID: 30051599.

299. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, **Kadia TM**, **DiNardo CD**, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 Oct; 132(16):1664-1674. PMID: 30185431 PMCID: PMC6265645.

300. **Kadia TM**, **Cortes J**, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541.

301. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, **Kadia T**. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 Sep; 59(9):2238-2241. PMID: 29338567.

302. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, **Kadia T**, **Pierce S**, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 Sep; 93(9):1136-1141. PMID: 30028037.

303. Assi R, Kantarjian HM, **Kadia TM**, **Pemmaraju N**, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 Jul; 124(13):2758-2765. PMID: 29660836.

304. Boddu P, Oviedo SP, Rausch CR, Yam C, Daver N, Kantarjian H, **Kadia TM**. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2018 Jun; 59(6):1-4. PMID: 28958191.

305. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, **Kadia T**, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 Jun; 59(6):1-11. PMID: 28972430 PMCID: PMC6120342.

306. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, **Kadia TM**, **Jabbour E**, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 Jun; 124(12):2534-2540. PMID: 29645075.

307. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, **Kadia T**, **Garcia-Manero G**, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695. PMID: 29464484.

308. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, **Kadia T**, **Jabbour E**, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 Jun; 36(18):1788-1797. PMID: 29702001 PMCID: PMC6008108.

309. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, **Kadia TM**, **Wierda WG**, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 Apr; 59(4):1-8. PMID: 28718728 PMCID: PMC5773400.

310. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, **Kadia TM**. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 Apr; 59(4):1-4. PMID: 28838278.

311. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, **Kadia T**, **Jabbour E**, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146. PMID: 29550383.

312. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, **Kadia TM**, **Jabbour EJ**, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. ePub 2018 Apr; PMID: 29749401 PMCID: PMC6202273.

313. DiNardo CD, Rausch CR, Benton C, **Kadia T**, **Jain N**, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in

Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. Am J Hematol. 2018 Mar; 93(3):401-407. PMID: 29218851.

314. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, **Kadia T**, **Pemmaraju N**, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb; 9(11):9714-9727. PMID: 29515765 PMCID: PMC5839396.

315. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, **Kadia T**, **Cortes J**, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb; 4(2):230-234. PMID: 28859185 PMCID: PMC5838597.

316. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, **Kadia T**, **Dinardo CD**, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol. 2018 Feb; 93(2):277-285. PMID: 29134664.

317. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 Feb; 19(2):240-248. PMID: 29352703.

318. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 Jan; 93(1):91-99. PMID: 29047158.

319. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, **Kadia T**, **Pemmaraju N**, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 Jan; 93(1):84-90. PMID: 29027261.

320. Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, **Kadia T**, **Jorgensen J**, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018; 7:26. PMID: 30323983 PMCID: PMC6174068.

321. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302. PMID: 28850699.

322. Abaza YM, **Kadia TM**, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec; 123(24):4851-4859. PMID: 28841236.

323. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, **Kadia TM**, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov; 123(22):4391-4402. PMID: 28743165 PMCID: PMC5673547.

324. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, **Kadia TM**, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov; 123(22):4430-4439. PMID: 28708931.

325. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in

Philadelphia negative metaphases during CML treatment. Blood. 2017 Nov; 130(19):2084-2091. PMID: 28835440 PMCID: PMC5680612.

326. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, **Kadia TM**, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct; 123(19):3717-3724. PMID: 28608976 PMCID: PMC5689475.

327. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, **Kadia TM**, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens. Am J Hematol. 2017 Oct; 92(10):E595-E597. PMID: 28646517 PMCID: PMC5689471.

328. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 Oct; 102(10):1709-1717. PMID: 28729302 PMCID: PMC5622855.

329. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. ePub 2017 Sep; PMID: 28919634.

330. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):845-850. PMID: 28494506.

331. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, **Kadia TM**, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 Sep; 31(9):1951-1961. PMID: 28042144 PMCID: PMC5537055.

332. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928. PMID: 28556489.

333. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep; 130(13):1514-1522. PMID: 28774880 PMCID: PMC5620419.

334. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, **Kadia TM**. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug; 123(16):3050-3060. PMID: 28387922 PMCID: PMC5544569.

335. Boddu P, Kantarjian H, Borthakur G, **Kadia T**, **Daver N**, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017 Aug; 1(19):1546-1550. PMID: 29296796 PMCID: PMC5728474.

336. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, **Kadia TM**. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul; 1(17):1312-1323. PMID: 29296774 PMCID: PMC5727976.

337. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682. PMID: 28370157 PMCID: PMC5580683.

338. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul; 18(8) PMID: 28933735 PMCID: PMC5578010.

339. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606. PMID: 28370097 PMCID: PMC5553721.

340. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 Jul; 31(7):1659. PMID: 28338082.

341. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, **Kadia TM**. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul; 28(7):1554-1559. PMID: 28379307 PMCID: PMC5834082.

342. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 May; 129(18):2584-2587. PMID: 28246192 PMCID: PMC5418636.

343. Boddu PC, **Kadia TM**. Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. Expert Rev Hematol. 2017 May; 10(5):1-16. PMID: 28452257.

344. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358. PMID: 28076892 PMCID: PMC5439522.

345. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, **Kadia TM**, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243. PMID: 28006851 PMCID: PMC5495018.

346. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 Mar; 129(10):1275-1283. PMID: 28003274 PMCID: PMC5413297.

347. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, **Kadia TM**, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar; 8(13):22104-22112. PMID: 27655665 PMCID: PMC5400650.

348. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 Mar; 31(3):678-687. PMID: 27677740 PMCID: PMC5345582.

349. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285. PMID: 28052371 PMCID: PMC5851443.

350. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, **Kadia TM**, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 Feb; 123(3):459-467. PMID: 27696391 PMCID: PMC5321542.

351. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, **Kadia TM**, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol. 2017 Feb; 92(2):155-160. PMID: 27874212 PMCID: PMC5338569.

352. Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol. 2017 Feb; 92(2):E14-E15. PMID: 27804182 PMCID: PMC5915352.

353. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 Feb; 123(3):426-435. PMID: 27657543 PMCID: PMC5258784.

354. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb; 123(4):629-637. PMID: 27741352.

355. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 Feb; 31(2):318-324. PMID: 27795561.

356. **Kadia TM**, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan; 10(1):1-8. PMID: 27869523 PMCID: PMC5578611.

357. Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N. Mixed angioinvasive Exserohilum and Scedosporium infection in a patient with AML. Am J Hematol. 2017 Jan; 92(1):119-120. PMID: 27341684 PMCID: PMC5884637.

358. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, **Kadia TM**, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. 2017 Jan; 52(1):28-33. PMID: 27595282 PMCID: PMC5849052.

359. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, **Kadia TM**, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 Jan; 123(2):294-302. PMID: 27602508 PMCID: PMC5321541.

360. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, Konopleva M, Jabbour E, Jain N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol. 2017; 2017:2413587. PMID: 29075538 PMCID: PMC5624137.

361. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec; 122(23):3650-3656. PMID: 27479888 PMCID: PMC5321539.

362. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 Dec; 91(12):1221-1226. PMID: 27474808 PMCID: PMC5118152.

363. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, **Kadia TM**, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec; 122(24):3812-3820. PMID: 27508525 PMCID: PMC5321530.

364. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):616-624. PMID: 27601000 PMCID: PMC5408349.

365. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov; 122(21):3336-3343. PMID: 27509035 PMCID: PMC5073019.

366. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 Oct; 6(10):1106-1117. PMID: 27520294 PMCID: PMC5436271.

367. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep. 2016 Aug; 4(8):765-7. PMID: 27525080 PMCID: PMC4974424.

368. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, **Kadia TM**, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 Aug; 91(8):819-23. PMID: 27178680 PMCID: PMC5558853.

369. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, **Kadia TM**, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 Aug; 122(16):2505-11. PMID: 27182988.

370. **Kadia TM**, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. ePub 2016 Jul; PMID: 27463065 PMCID: PMC5269552.

371. **Kadia TM**. Personalized treatment for patients with myelofibrosis. Clin Adv Hematol Oncol. 2016 Jun; 14(6):400-3. PMID: 27379807.

372. Wang W, Tang G, Kadia T, Lu X, Li Y, Huang L, Montenegro-Garreaud X, Miranda RN, Wang SA. Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement. J Natl Compr Canc Netw. 2016 Jun; 14(6):708-11. PMID: 27283163.

373. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, **Kadia TM**, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008.

374. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 Jun; 122(12):1871-9. PMID: 26990290.

375. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr; 127(15):1863-9. PMID: 26747249 PMCID: PMC4915808.

376. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26. PMID: 26846160 PMCID: PMC4809772.

377. **Kadia TM**. Release the hounds: virotherapy with immunotherapy. Blood. 2016 Mar; 127(11):1381-3. PMID: 26989187 PMCID: PMC4797017.

378. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar; 7(12):14172-87. PMID: 26871476 PMCID: PMC4924706.

379. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-168.e2. PMID: 26752456 PMCID: PMC4804759.

380. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62. PMID: 26796981 PMCID: PMC4769134.

381. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, **Kadia TM**, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2016 Mar; 127(10):1269-75. PMID: 26729897 PMCID: PMC4786836.

382. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205 PMCID: PMC4826052.

383. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73. PMID: 26365212 PMCID: PMC4790089.

384. **Kadia TM**, Ravandi F. Alemtuzumab in T-cell large granular lymphocyte leukaemia. Lancet Haematol. 2016 Jan; 3(1):e4-5. PMID: 26765647.

385. Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J. 2015 Dec; 5:e375. PMID: 26657199 PMCID: PMC4735070.

386. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74. PMID: 26547258 PMCID: PMC4822515.

387. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-55. PMID: 26432046 PMCID: PMC4816046.

388. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, **Kadia TM**, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70. PMID: 26299958 PMCID: PMC4618182.

389. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73. PMID: 26017166 PMCID: PMC4546505.

390. **Kadia TM**, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol. 2015 Sep; 1(6):820-8. PMID: 26181162.

391. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6. PMID: 26016821 PMCID: PMC4612499.

392. Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug; 33(4):870-80. PMID: 25933833.

393. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3. PMID: 25716073 PMCID: PMC4977576.

394. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63. PMID: 26088933 PMCID: PMC5004422.

395. **Kadia TM**, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul; 121(14):2375-82. PMID: 25809968.

396. **Kadia TM**, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia (AML) and higher blast counts. Am J Hematol. 2015 Jul; 90(7):E139-41. PMID: 25858582 PMCID: PMC4478207.

397. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34. PMID: 25682597 PMCID: PMC4486227.

398. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. 2015 May; 56(5):1-12. PMID: 25120050 PMCID: PMC4417657.

399. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61. PMID: 25682595 PMCID: PMC4420214.

400. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81. PMID: 25530214 PMCID: PMC4376596.

401. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1-8. PMID: 25048874 PMCID: PMC4326620.

402. **Kadia TM**, Ravandi F, Cortes J, Kantarjian H. Towards Individualized Therapy in Acute Myeloid Leukemia. JAMA Oncol. Published online April 30, 2015. doi:10.1001/jamaoncol.2015.0617. 2015 Apr.

403. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82. PMID: 25410759 PMCID: PMC4378905.

404. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6. PMID: 25441108 PMCID: PMC4344906.

405. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53. PMID: 25312977 PMCID: PMC4323735.

406. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6. PMID: 25407953.

407. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes. Leuk Lymphoma. 2015 Feb; 56(2):1-21. PMID: 24844364 PMCID: PMC4297591.

408. **Kadia TM**, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968 PMCID: PMC4447180.

409. **Kadia TM**, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, and Kantarjian H. Final Results of the Phase II Trial of Clofarabine and Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancer. 2015 Feb.

410. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20. PMID: 26687423 PMCID: PMC4936479.

411. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. Biomed Res Int. 2015; 2015:497597. PMID: 25654108 PMCID: PMC4310492.

412. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, **Kadia TM**, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398 PMCID: PMC4239168.

413. Dinardo CD, Daver N, Jabbour E, **Kadia T**, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Piece S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian H, and Garcia-Manero G. Sequential azacytidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm phase I/II study. The Lancet Hematology. 2014 Dec.

414. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, **Kadia TM**, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8. PMID: 24990142 PMCID: PMC4431614.

415. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590 PMCID: PMC4167474.

416. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9. PMID: 25047979 PMCID: PMC4157096.

417. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9. PMID: 24138309 PMCID: PMC4139917.

418. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44. PMID: 24004182 PMCID: PMC4143910.

419. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M. Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4. PMID: 24033106 PMCID: PMC4105975.

420. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30. PMID: 24355079 PMCID: PMC4096861.

421. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659 PMCID: PMC4182922.

422. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16. PMID: 24458781 PMCID: PMC4221257.

423. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, **Kadia TM**, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795 PMCID: PMC3989412.

424. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.

425. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71. PMID: 24461514 PMCID: PMC4167660.

426. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1. PMID: 24332214 PMCID: PMC3959284.

427. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014 Apr; 5(2):29-34. PMID: 24688752 PMCID: PMC3949300.

428. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4. PMID: 23890523 PMCID: PMC4232180.

429. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926 PMCID: PMC4110914.

430. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6. PMID: 23790798 PMCID: PMC4120256.

431. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779 PMCID: PMC3923606.

432. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. 2013 Sep; 54(9):2070-2. PMID: 23320889 PMCID: PMC4114215.

433. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81. PMID: 23969309 PMCID: PMC4101888.

434. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94. PMID: 23969308 PMCID: PMC4120258.

435. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521 PMCID: PMC3674666.

436. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829 PMCID: PMC4089101.

437. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353 PMCID: PMC4181539.

438. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200. PMID: 23345254 PMCID: PMC4085133.

439. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 study of anti-CD33 immunotoxin HUM-195/rGEL in patients withadvanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21. PMID: 22875630 PMCID: PMC3561428.

440. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9. PMID: 23115106 PMCID: PMC4085099.

441. Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22. PMID: 22605576 PMCID: PMC4184417.

442. **Kadia TM**, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9. PMID: 22569880 PMCID: PMC3416961.

443. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70. PMID: 22252728 PMCID: PMC3913560.

444. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348 PMCID: PMC3907176.

445. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9. PMID: 22718840 PMCID: PMC4081158.

446. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616 PMCID: PMC3859239.

447. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5. PMID: 22532519 PMCID: PMC3409823.

448. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 2012 Jul 15; 118(14):3556-64. PMID: 22139909 PMCID: PMC4984525.

449. Sharp H, Grosshans D, Kadia T, Dabaja BS. Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia. BMJ Case Rep. 2012 Jul 11; 2012 PMID: 22787181 PMCID: PMC3417036.

450. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, **Kadia TM**, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10. PMID: 22585696 PMCID: PMC4879705.

451. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15. PMID: 21494838 PMCID: PMC4205950.

452. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814 PMCID: PMC4050633.

453. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73. PMID: 22020636 PMCID: PMC4060157.

454. **Kadia TM**, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602 PMCID: PMC3924750.

455. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624 PMCID: PMC3311242.

456. Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: clinical outcome analysis of 123 patients. Haematologica. 2012 Feb; 97(2):235-40. PMID: 22058194 PMCID: PMC3269483.

457. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9. PMID: 22072492 PMCID: PMC4085038.

458. **Kadia TM**, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92. PMID: 21943675 PMCID: PMC4098768.

459. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8. PMID: 21747082 PMCID: PMC4874216.

460. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694 PMCID: PMC4874214.

461. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9. PMID: 20668231 PMCID: PMC4081299.

462. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy. 2010 Oct; 6(7):976-8. PMID: 20729640.

463. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The Combination of a Histone Deacecetylase Inhibitor with the BH3-Mimetic GX15-070 has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clin Cancer Res. 2010 Aug 01; 16(15):3923-32. PMID: 20538760 PMCID: PMC4113507.

464. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk. 2010 Aug; 10(4):301-2. PMID: 20709669.

465. **Kadia TM**, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82. PMID: 20456355 PMCID: PMC4124904.

466. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7. PMID: 20008621 PMCID: PMC2815701.

467. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb; 113(9):1892-8. PMID: 19109226 PMCID: PMC2651008.

468. Mendez J, **Kadia TM**, Somayazula RK, El-Badawi KI, Cowen DS. Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. J Neurochem. 1999 Jul; 73(1):162-8. PMID: 10386967.

JOURNAL ARTICLES - EDITORIALS

1. Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, **Kadia TM**, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, Jabbour EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood. 2016 Dec; 128(22):2917.

JOURNAL ARTICLES - LETTERS TO THE EDITOR

1. Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, **Kadia, TM**, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal. 2025 Dec 01; 15(1) PMID: 40175328 PMCID: PMC11965427.

2. Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, **Kadia, TM**, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica. 2025 Jul 01; 110(7):1628-1633. PMID: 39973365 PMCID: PMC12208154.

3. Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, **Kadia, TM**, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation. 2025 Jun 01; 60(6):910-913. PMID: 40217110 https://doi.org/10.1038/s41409-025-02590-6.

4. Kawedia, J, Rausch, C, Liu, X, Qiao, W, DiNardo, C, Daver, N, Borthakur, G, Pemmaraju, N, Reville, PK, Kontoyiannis, DP, Short, NJ, Konopleva, M, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, **Kadia, TM**. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. American journal of hematology. 2025 Apr 01; 100(4):740-743. PMID: 39873236 PMCID: PMC11888890.

5. Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, **Kadia, TM**, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia. 2025 Feb 01; 39(2):524-528. PMID: 39551874 https://doi.org/10.1038/s41375-024-02457-7.

6. Tremblay, D, Csizmar, C, DiNardo, C, Ball, S, Rippel, N, Hammond, DE, **Kadia, TM**, Ravandi, F, Chien, KS, Van Hyfte, G, Mazumdar, M, Saliba, AN, Mangaonkar, AA, Lasho, T, Al-Kali, A, Kremyanskaya, M, Feld, J, Silverman, LR, Komrokji, RS, Mascarenhas, J, Padron, E, Garcia-Manero, G, Sallman, D, Patnaik, MM, Montalban Bravo, G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia. Leukemia. 2025 Jan 01; 39(1):257-260. PMID: 39533069 https://doi.org/10.1038/s41375-024-02466-6.

7. Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, **Kadia, TM**, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic

leukemia receiving inotuzumab ozogamicin. Blood cancer journal. 2024 Dec 01; 14(1) PMID: 39112504 PMCID: PMC11306742.

8. Ravandi, F, Senapati, J, Jain, N, Short, NJ, **Kadia, TM**, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec 01; 38(12):2717-2721. PMID: 39322712 https://doi.org/10.1038/s41375-024-02414-4.

9. Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, **Kadia, TM**, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia. 2024 Oct 01; 24(10):732-735. PMID: 38945779 https://doi.org/10.1016/j.clml.2024.06.001.

10. Bose, P, Masarova, L, Pemmaraju, N, Bledsoe, S, Daver, N, Jabbour, EJ, **Kadia, TM**, Estrov, Z, Kornblau, SM, Andreeff, M, Jain, N, Cortes, JE, Borthakur, G, Alvarado, Y, Richie, MA, Dobbins, MH, McCrackin, SA, Zhou, L, Pierce, S, Wang, X, Pike, A, Garcia-Manero, G, Kantarjian, H, Verstovsek, S. Sotatercept for anemia of myelofibrosis. Haematologica. 2024 Aug 01; 109(8):2660-2664. PMID: 38572554 PMCID: PMC11290543.

11. Abuasab, T, Borthakur, G, Kanagal Shamanna, R, Masarova, L, Patel, KP, Takahashi, K, Bose, P, Villarreal, J, Pierce, S, **Kadia, TM**, Garcia-Manero, G, Short, NJ, DiNardo, C, Daver, N, Ravandi-Kashani, F, Kantarjian, H, Verstovsek, S, Yilmaz, M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms. American journal of hematology. 2024 Jul 01; 99(7):1434-1436. PMID: 38613831 https://doi.org/10.1002/ajh.27333.

12. Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, **Kadia, TM**, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 May 01; 38(5):1178-1181. PMID: 38418609 https://doi.org/10.1038/s41375-024-02190-1.

13. Bataller, A, DiNardo, C, Bazinet, A, Daver, N, Maiti, A, Borthakur, G, Short, NJ, Sasaki, K, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, **Kadia, TM**. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. American journal of hematology. 2024 Apr 01; 99(4):792-796. PMID: 38361282 https://doi.org/10.1002/ajh.27236.

14. Herling, M, Dearden, C, Zaja, F, El-Sharkawi, D, Ding, W, Bellido, M, Khot, A, Tick, L, Jacobsen, ED, Eyre, TA, Roos-Weil, D, **Kadia, TM**, Lucchini, E, Pflug, N, Davids, MS, Pena, G, Mukherjee, N, Badawi, M, Vizkelety, T, Staber, PB. Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia. Blood Advances. 2024 Feb 27; 8(4):842-845. PMID: 38190628 PMCID: PMC10874748.

15. Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, **Kadia, TM**, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal. 2023 Dec 01; 13(1) PMID: 37735426 PMCID: PMC10514257.

JOURNAL ARTICLES - BRIEF COMMUNICATIONS

1. Fiskus, WC, Mill, CP, Birdwell, C, Davis, JA, Das, K, Boettcher, S, **Kadia, TM**, DiNardo, C, Takahashi, K, Loghavi, S, Soth, MJ, Heffernan, TP, McGeehan, G, Ruan, X, Su, X, Vakoc, CR, Daver, N, Bhalla, K. Correction to. Blood cancer journal. 2025 Dec 01; 15(1) PMID: 40399254 PMCID: PMC12095577.

JOURNAL ARTICLES - REVIEW ARTICLES

1. Senapati, J, **Kadia, TM**, Daver, N, DiNardo, C, Borthakur, G, Ravandi-Kashani, F, Kantarjian, HM. Therapeutic horizon of acute myeloid leukemia. Cancer. 2025 Apr 01; 131(7) PMID: 40105906 https://doi.org/10.1002/cncr.35806.

2. Goulart, H, Wei, A, **Kadia, TM**. Maintenance Therapy in AML. American journal of hematology. 2025 Mar 01; 100(S2):38-49. PMID: 39960005 https://doi.org/10.1002/ajh.27583.

3. Kantarjian, HM, DiNardo, C, **Kadia, TM**, Daver, N, Altman, JK, Stein, EM, Jabbour, EJ, Schiffer, CA, Lang, A, Ravandi-Kashani, F. Acute myeloid leukemia management and research in 2025. Ca-A Cancer Journal for Clinicians. 2025 Jan 01; 75(1):46-67. PMID: 39656142 PMCID: PMC11745214.

4. Goulart, H, Kantarjian, HM, Pemmaraju, N, Daver, N, DiNardo, C, Rausch, CR, Ravandi-Kashani, F, **Kadia, TM**. Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood cancer discovery. 2025 Jan 01; 6(1):23-37. PMID: 39565177 PMCID: PMC11707511.

5. Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, **Kadia, TM**, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal. 2024 Dec 01; 14(1) PMID: 39300079 PMCID: PMC11413327.

6. Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, **Kadia, TM**, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia. 2024 Oct 01; 38(10):2073-2084. PMID: 39179671 PMCID: PMC11436367.

7. Jen, WY, Kantarjian, HM, **Kadia, TM**, DiNardo, C, Issa, GC, Short, NJ, Yilmaz, M, Borthakur, G, Ravandi-Kashani, F, Daver, N. Combination therapy with novel agents for acute myeloid leukaemia. British Journal of Haematology. 2024 Jul 01; 205(1):30-47. PMID: 38724457 PMCID: PMC12068000.

8. Zimmer, M, **Kadia, TM**. Approach to the Older Patient with Acute Myeloid Leukemia. Current oncology reports. 2023 Nov 01; 25(11):1203-1211. PMID: 37688738 https://doi.org/10.1007/s11912-023-01450-0.

9. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 Sep; 98(9):1383-1393. PMID: 37334870 PMCID: PMC12045478.

10. Daver NG, Maiti A, **Kadia TM**, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 Nov 02; 12(11):2516-2529. PMID: 36218325 PMCID: PMC9627130.

11. Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022 Jun 09; 12(6):91. PMID: 35680852 PMCID: PMC9184476.

12. Senapati J, **Kadia TM**. Which FLT3 Inhibitor for Treatment of AML? Curr Treat Options Oncol. 2022 Mar; 23(3):359-380. PMID: 35258791 https://doi.org/10.1007/s11864-022-00952-6.

13. Bazinet A, **Kadia TM**. Changing paradigms in the treatment of acute myeloid leukemia in older patients. Clin Adv Hematol Oncol. 2022 Jan; 20(1):37-46. PMID: 35060961.

14. Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, **Kadia TM**, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 Apr 27; 5(8):2156-2164. PMID: 33885751 PMCID: PMC8095138.

15. Kantarjian HM, **Kadia TM**, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 Apr 15; 127(8):1186-1207. PMID: 33734442 PMCID: PMC12084862.

16. Birdwell C, Fiskus W, **Kadia TM**, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021 Mar 22; 11(3):64. PMID: 33753715 PMCID: PMC7985498.

17. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol. E-pub ahead of print: 2021 Mar 01; 144(2):1-13. PMID: 32392559 PMCID: PMC7270066.

18. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 Feb; 11(2):41. PMID: 33619261 PMCID: PMC7900255.

19. Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021; 11:656218. PMID: 34041025 PMCID: PMC8143531.

20. Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11:639387. PMID: 33898313 PMCID: PMC8063727.

21. Reville PK, Kadia T. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. Curr Treat Options Oncol. 2020 Apr 21; 21(4):34. PMID: 32318829.

22. Short NJ, Konopleva M, **Kadia TM**, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. 2020 Apr; 10(4):506-525. PMID: 32014868.

23. Reville PK, **Kadia TM**. Maintenance Therapy in AML. Front Oncol. 2020; 10:619085. PMID: 33604298 PMCID: PMC7884813.

24. Paul S, DiPippo AJ, Ravandi F, **Kadia TM**. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. Future Oncol. 2019 Dec; 15(34):3885-3894. PMID: 31559849.

25. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 Dec; 94(12):1388-1395. PMID: 31595534.

26. Molica M, Breccia M, Foa R, Jabbour E, **Kadia TM**. Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019 Nov; 94(11):1254-1265. PMID: 31429099.

27. Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, **Kadia TM**, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 Oct; 134(14):1132-1143. PMID: 31292114 PMCID: PMC7042666.

28. **Kadia TM**, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget. 2019 Feb; 10(12):1250-1265. PMID: 30815228 PMCID: PMC6383813.

29. Boddu PC, **Kadia TM**. Molecular pathogenesis of acquired aplastic anemia. Eur J Haematol. 2019 Feb; 102(2):103-110. PMID: 30380171.

30. Klepin HD, Estey E, Kadia T. More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:421-432. PMID: 31099627.

31. Khan M, Mansoor AE, **Kadia TM**. Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncol. 2017 Mar; 13(6):523-535. PMID: 27771959 PMCID: PMC5296715.

32. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb; 110:20-34. PMID: 28109402 PMCID: PMC5410376.

33. **Kadia TM**, Ravandi F, Cortes J, Kantarjian H. New drugs in acute myeloid leukemia. Ann Oncol. 2016 May; 27(5):770-8. PMID: 26802152 PMCID: PMC4843183.

34. **Kadia TM**, Ravandi F, O'Brien S, Cortes J, Kantarjian HM. Progress in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51. PMID: 25441110 PMCID: PMC4344862.

35. Willis L, Rexwinkle A, Bryan J, **Kadia TM**. Recent Developments in Drug Therapy for Aplastic Anemia. Ann Pharmacother. 2014 Nov; 48(11):1469-1478. PMID: 25184310.

36. **Kadia TM**, Garcia-Manero G. Role of epigenetic therapy in myelodysplastic syndrome. Expert Rev Hematol. 2008 Dec; 1(2):161-174. PMID: 21082921 PMCID: PMC3833719.

JOURNAL ARTICLES - CASE STUDY/STUDIES

1. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, **Kadia TM**, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol. 2020; 10:588876. PMID: 33194747 PMCID: PMC7606916.

2. Messer A, Brown AE, Pacha O, Boddu P, Geppner A, **Kadia TM**, Huen AO. Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod. JAAD Case Rep. 2019 Nov; 5(11):979-981. PMID: 31709290 PMCID: PMC6835029.

3. Jain P, Sargent RL, Konoplev SN, Benjamini O, Kantarjian H, Kadia T. Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. Am J Hematol. 2013 May; 88(5):433-4. PMID: 23460270.

4. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol. 2009 Aug; 94(1):149-52. PMID: 19219404 PMCID: PMC4438990.

JOURNAL ARTICLES - ABSTRACTS

1. Jain N, Ferrajoli A, Basu S, Thompson PA, Burger JA, **Kadia TM**, Estrov ZE, Pemmaraju N, Lopez W, Thakral B, Khoury JD, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison JP, Keating MJ, Sharma P, Wierda WG. A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. Blood. 2018 Dec; 132(Suppl 1):296.

2. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, F-Kashani R, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, **Kadia TM**, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 Dec; 132(Suppl 1):1664-1674.

3. Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi R, Sun B, PeterMill C, Nowak AJ, Kornblau SM, Bose P, **Kadia TM**, DiNardo CD, LuciaMasarova, Horrigan S, Khoury JD, Sharma S, N Bhalla VSAK. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood. 2018 Dec; 132(Suppl 1):177.

4. Sasaki K, Kantarjian HM, Short NJ, Ravandi F, Khouri M, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Jacob J, Garris RE, Yilmaz M, Thompson PA, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Jabbour EJ. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood. 2018 Dec; 132(Suppl 1):34.

5. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, **Kadia TM**, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood. 2018 Dec; 132(Suppl 1).

6. Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, BBenton C, **Kadia TM**, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, LuciaMasarova, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos, A, Ma H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 2018 Dec; 132(Suppl 1):286.

7. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, YesidAlvarado, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, **Kadia TM**, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood. 2018 Dec; 132(Suppl 1):232.

8. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, YesidAlvarado, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, KiranNaqvi, Cortes JE, **Kadia TM**, Konopleva MY, Colla S, Yang H, Rausch CR, YvonneGasior, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood. 2018 Dec; 132(Suppl 1):465.

9. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, **Kadia TM**, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood. 2018 Dec; 132(Suppl 1).

10. Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, **Kadia TM**, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Nogueras González GM, Kornblau SM, MansourAlfayez, Matthews J, Flores W, Blando J, Allison JP, Sharma P, Kantarjian HM. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood. 2018 Dec; 132(Suppl 1):906.

11. Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebriaei P, Huang X, ERytting M, Jain N, Konopleva MY, Garcia-Manero G, Champlin RE, **Kadia TM**, ECortes J, Estrov ZE, Takahashi K, Mace M, Khouri M, Nasnas P, Jacob J, EGarris R, Jabbour EJ. Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood. 2018 Dec; 132(Suppl 1):553.

12. Rampal RK, Verstovsek S, Devlin SM, Stein EM, **Kadia TM**, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial results of a Phase II Study. Blood. 2018 Dec; 132(Suppl 1):354.

13. Mill CP, Cai T, Fiskus W, Borthakur G, Kornblau SM, **Kadia TM**, DiNardo CD, Nowak AJ, Saenz DT, Saenz DN, Sun B, Ganesh T, WendyJin, Rao V, Khoury JD, Shen Y, N Bhalla KMAK. Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. Blood. 2018 Dec; 132(Suppl 1):1351.

14. Kanagal-Shamanna R, Sasaki K, Bravo GM, Benton CB, Jabbour EJ, Borthakur G, **Kadia TM**, Bueso-Ramos CE, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):1820.

15. Fiskus W, Mill CP, Soldi R, Han R, Saenz DT, Nowak AJ, Sun B, Saenz DN, DiNardo CD, Borthakur G, **Kadia TM**, Jin W, Ganesh T, Rao V, Khoury JD, Sharma S, Bhalla KN. Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells. Blood. 2018 Dec; 132(Suppl 1):3930.

16. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Alvarado Y, **Kadia TM**, Kantarjian HM, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood. 2018 Dec; 132(Suppl 1):2667.

17. Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, **Kadia TM**, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood. 2018 Dec; 132(Suppl 1):1831.

18. Tallis E, Kantarjian HM, Major CK, Vazquez M, Borthakur G, Bose P, Ravandi F, Garcia-Manero G, **Kadia TM**, Wierda WG, Ferrajoli A, Pemmaraju N, Daver NG, DiNardo CD, Konopleva MY, Kornblau SM, Champlin RE, Jabbour EJ, Pierce SA, Cortes JE. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKI. Blood. 2018 Dec; 132(Suppl 1):2702.

19. Alfayez M, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Cortes JE, **Kadia TM**. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1).

20. Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, EEstrov Z, **Kadia TM**, Takahashi K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood. 2018 Dec; 132(Suppl 1):695.

21. **Kadia TM**, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Bhalla KN, Pemmaraju N, Jain N, Malla R, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood. 2018 Dec; 132(Suppl 1):4057.

22. Aboudalle I, Kantarjian HM, Ravandi F, Jabbour EJ, Daver NG, Estrov ZE, MichaelAndreeff, Ferrajoli A, DiNardo CD, Pemmaraju N, Naqvi K, Jain N, GwenPelletier S, Garcia-Manero G, Cortes JE, **Kadia TM**. Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. Blood. 2018 Dec; 132(Suppl 1):2714.

23. Alfayez M, Kantarjian HM, Short NJ, Assi R, Khouri M, Ravandi F, Paul S, Rausch CR, Nasnas P, Borthakur G, DiNardo CD, **Kadia TM**, Daver NG, Garcia-Manero G, Naqvi K, Bose P, O'Brien SM, Cortes JE, Jabbour EJ. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood. 2018 Dec; 132(Suppl 1):2702.

24. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, **Kadia TM**, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour EJ, Verstovsek S. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood. 2018 Dec; 132(Suppl 1):687.

25. Bose P, McCue D, Wiederhold NP, **Kadia TM**, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood. 2018 Dec; 132(Suppl 1).

26. Masarova L, Cortes JE, Patel KP, O'Brien SM, Nogueras González GM, Konopleva MY, Verstovsek S, Garcia-Manero G, Ferrajoli A, **Kadia TM**, Ravandi F, Borthakur G, Dellasala SE, Jabbour EJ, Kantarjian HM. Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood. 2018 Dec; 132(Suppl 1):3011.

27. Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju N, **Kadia TM**, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood. 2018 Dec; 132(Suppl 1):2544.

28. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, **Kadia TM**, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood. 2018 Dec; 132(suppl 1):2791.

29. Montalban Bravo G, Kanagal-Shamanna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, **Kadia TM**, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, EBueso-Ramos C, Patel K, Kantarjian HM, Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood. 2018 Dec; 132(Suppl 1):1514.

30. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Jeanis V, Alvarez J, Khouri M, Nasnas P, Garris RE, Wierda WG, Thompson PA, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood. 2018 Dec; 132(Suppl 1):2695.

31. Yalniz F, Kantarjian HM, **Kadia TM**, Garcia-Manero G, Patel K, Loghavi S, KojiSasaki, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood. 2018 Dec; 132(Suppl 1):3983.

32. Major CK, Kantarjian HM, Borthakur G, **Kadia TM**, Pemmaraju N, JShort N, Daver NG, Jabbour EJ, Champlin RE, Garcia-Manero G, Konopleva MY, Andreeff M, Kornblau SM, Wierda WG, Pierce SA, Ravandi F, Cortes JE. Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood. 2018 Dec; 132(Suppl 1):3976.

33. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, AThompson P, Borthakur G, **Kadia TM**, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, Flores W, Basu S, Allison JP, Sharma P, Pierce SA, Pike A, Cortes JE, Ravandi F. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood. 2018 Dec; 132(Suppl 1):905.

34. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, **Kadia TM**, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood. 2018 Dec; 132(Suppl 1):84.

35. Chamoun K, Kantarjian HM, Naqvi K, Wang X, Garcia-Manero G, Borthakur G, Jabbour EJ, **Kadia TM**, Daver NG, DiNardo CD, Jain N, Konopleva MY, ECortes J, Ravandi F, Yilmaz M. Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). Blood. 2018 Dec; 132(Suppl 1).

36. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Naqvi K, Pierola AA, Yilmaz M, Short NJ, Jabbour EJ, Ravandi F, **Kadia TM**, Pierce SA, Takahashi K, DiNardo CD, Nogueras González GM, Abaza Y, Devendra KC, Chamoun K, Sakurai K, Patel KP, Cortes JE, Kantarjian HM, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):4359.

37. Wang F, Morita K, DiNardo CD, Patel K, MacBeth K, Tosolini A, Frattini MG, Matthews J, Little L, Gumbs C, Tippen S, Song X, Zhang J, Thompson E, **Kadia TM**, Garcia-Manero G, Jabbour EJ, Ravandi F, Konopleva MY, Kantarjian HM, Futreal A, Takahashi K. Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance. Blood. 2018 Dec; 132(Suppl 1):441.

38. Aboudalle I, Kantarjian HM, Ohanian MN, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, **Kadia TM**, Ravandi F, Cortes JE. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood. 2018 Dec; 132(Suppl 1):2715.

39. Aboudalle I, Kantarjian HM, Short NJ, Konopleva MY, Jain N, Garcia-Manero G, Garris RE, Qiao W, Cortes JE, O'Brien SM, Kebriaei P, **Kadia TM**, Jabbour EJ, Ravandi F. Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. Blood. 2018 Dec; 132(Suppl 1):2659.

40. Alfayez M, Kantarjian HM, Ravandi F, Konopleva MY, Garcia-Manero G, MKadia T, Jabbour EJ, Borthakur G, DiNardo CD, Estrov ZE, Pemmaraju N, Pierce SA, Yilmaz ME, Short NJ, Takahashi K, Assi. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood. 2018 Dec; 132(Suppl 1):663.

41. Swaminathan M, Kantarjian HM, Sasaki K, Ravandi F, Borthakur G, **Kadia TM**, Garcia-Manero G, DiNardo CD, Konopleva MY, Estrov ZE, Pemmaraju N, Daver NG, Wierda WG, Ferrajoli A, Pierce SA, Dellasala MDE, Jabbour EJ, Cortes JE. Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):3013.

42. Assi R, Boddu P, **Kadia TM**, Estrov ZE, Garcia-Manero G, Ravandi F, Jabbour EJ, Takahashi K, Konopleva MY, Andreeff M, Zahr AA, DiNardo CD, Borthakur G, Jain N, Pemmaraju N, Yilmaz ME, Short NJ, Ning J, Pierce SA, Wierda WG, Cortes JE, Kantarjian HM, Daver NG. Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. Blood. 2018 Dec; 132(Suppl 1):3689.

43. Tallis E, Benton CB, Khan A, Assi R, DiNardo CD, Hornbaker MJ, Major CK, Boddu P, Kanagal-Shamanna R, Patel KP, Daver NG, Takahashi K, Montalban-Bravo G, **Kadia TM**, Konopleva MY, Andreeff M, Kantarjian HM, Garcia-Manero G. Diverse Landscape of TET2 Variants in MDS and AML. Blood. 2018 Dec; 132(Suppl 1).

44. DiNardo CD, Albitar M, **Kadia TM**, Naqvi K, Vaughan K, Cavazos, A, Pierce SA, Takahashi K, Kornblau SM, Ravandi F, Cortes JE, Kantarjian HM, Konopleva MY. Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study. Blood. 2018 Dec; 132(Suppl 1).

45. Ravandi F, Pierce SA, Garcia-Manero G, **Kadia TM**, Jabbour EJ, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes JE, Kim C, AKelsh M, Katz AJ, Williams R, Yang Z, Mehta B, Kantarjian HM. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):3985.

46. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, **Kadia TM**, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood. 2018 Dec; 132(Suppl 1):36.

47. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2018 Dec; 132(Suppl 1).

48. Masarova L, Daver NG, **Kadia TM**, Pemmaraju N, Jabbour EJ, Zhou L, Pierce SA, Cortes JE, Kantarjian HM, Verstovsek S. Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study. Blood. 2018 Dec; 132(Suppl 1):1764.

49. Rausch CR, Paul S, Montalban Bravo G, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, **Kadia TM**, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood. 2018 Dec; 132(Suppl 1).

50. Yalniz F, Kantarjian HM, Borthakur G, **Kadia TM**, Daver NG, Pemmaraju N, Konopleva MY, Garcia-Manero G, Takahashi K, DiNardo CD, Bose P, Andreeff M, Ravandi F, Cortes JE. Potential Predictors of Induction Failure and Complete Remission Duration inFLT3-ITD Mutated Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):3996.

51. Daver NG, Assi R, Kantarjian HM, Cortes JE, Ravandi F, Konopleva MY, MKadia T, Borthakur G, Jabbour EJ, DiNardo CD, Velasquez M, Kelly M, Ning J, Nogueras González GM, Pierce SA, Gombos D, Estrov ZE, Kornblau SM, Zhang W, Andreeff M. Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). Blood. 2018 Dec; 132(Suppl 1):1441.

52. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Estrov ZE, Garris RE, Khouri M, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood. 2018 Dec; 132(Suppl 1):2664.

53. Morita K, Wang F, Makishima H, Yan Y, Yoshizato T, Yoshida K, PPrzychodzen B, Patel K, Bueso-Ramos CE, Gumbs C, Little L, Tippen S, Zhang J, Song X, **Kadia TM**, Daver NG, Pemmaraju N, DiNardo CD, Ravandi F, SrdanVerstovsek, Jabbour EJ, Cortes JE, Kantarjian HM, Garcia-Manero G, PMaciejewski J, Ogawa S, P Andrew Futreal P, Takahashi K. Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. Blood. 2018 Dec; 132(Suppl 1):1801.

54. Swaminathan M, Morita K, Yuanqing Y, Wang F, Burks J, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Zhang J, Song X, DiNardo CD, Jabbour EJ, **Kadia TM**, Cortes JE, Daver NG, Pemmaraju N, Patel K, Garcia-Manero G, Kantarjian HM, Bueso-

Ramos CE, Futreal A, Takahashi K. Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. Blood. 2018 Dec; 132(Suppl 1):5240.

55. Swaminathan M, Stavrou N, Antzoulatos S, Albitar M, Patel K, Cortes JE, DiNardo CD, **Kadia TM**, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Borthakur G. RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. Blood. 2018 Dec; 132(Suppl 1):5113.

56. Alfayez M, Kantarjian HM, **Kadia TM**, Garcia-Manero G, Ravandi F, Borthakur G, DiNardo CD, Rios MB, Jabbour EJ, Cortes JE. Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. Blood. 2018 Dec; 132(Suppl 1):5447.

57. Ghorab A, Patel K, Cortes JE, Chihara D, Price A, **Kadia TM**, Ravandi F, Pemmaraju N, Daver NG, Dinardo CD, Kantarjian HM, G; B. Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation. J Clin Oncol. 2018 Jun; 36(Suppl; abstr 7069).

58. Chamoun K, Kantarjian HM, Akosile MA, Assi R, Ravandi F, Borthakur G, Garcia-Manero G, Kadia T, Konopleva M, Estrov Z, DiNardo CD, Daver N, Pemmaraju N, Ferrajoli A, Burger JA, Wierda W, Jabbour EJ and Cortes JE. Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience. Blood. 2017 Dec; 130(Suppl 1):1594.

59. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Takahashi K, Kadia T, Saenz DT, Nowak AJ, Sun B, N Bhalla CMCAK. Targeted Therapy for AML Expressing RUNX1 Mutation. Blood. 2017 Dec; 130(Suppl 1):2472.

60. Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Wierda WG, Borthakur G, Naqvi K, Pemmaraju N, DiNardo CD, Daver N, Yilmaz M, Patel K, Linderman DB, Garris R, Jabbour EJ and Kantarjian HM. Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase. Blood. 2017 Dec; 130(Suppl 1):143.

61. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour EJ, DiNardo CD, Daver N, Jain N, Pemmaraju N, Jorgensen JL, Wang SA, Andreeff M, Cortes JE, Kantarjian HM and Kadia T. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities. Blood. 2017 Dec; 130(Suppl 1):1419.

62. Issa GC, Kantarjian HM, Wang F, González GN, Borthakur G, Tang G, Bueso-Ramos CE, Kanagal-Shamanna R, Hidalgo Lopez JE, Zhao C, Coyle M, Takahashi K, Preetesh J, Ravandi F, Kadia T, Garcia-Manero G, Jabbour EJ, Futreal A and Cortes JE. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML. Blood. 2017 Dec; 130(Suppl 1):47.

63. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H and Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Dec; 130(Suppl 1):1514-1522.

64. Yilmaz M, Devendra KC, Akosile MA, Khoury JD, Short NJ, Cortes JE, Garcia-Manero G, Ravandi F, Kadia T, Sasaki K, Konopleva M, Wierda WG, NitinJain, Verstovsek S, Estrov Z, Pierce S, O'Brien SM, Jabbour EJ and Kantarjian HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 2017 Dec; 130(Suppl 1):2712.

65. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Rubenstein SE, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger S, Butrym A, Gaidano G, Thomas X, Montesinos P, Rizzieri DA, Quick DP, Agura E, Venugopal P, JanakiramanSubramanian, Maness LJ, Robert D, Hicheri Y, Kadia T, Ravandi F, Marc. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood. 2017 Dec; 130(Suppl 1):891.

66. Benton CB, Khan M, González GN, Nazha A, Piao J, Ning J, Aung FM, Jabbour EJ, Kadia T, Borthakur G, Ravandi F, Komrokji RS, Steensma DP, EDeZern A, Roboz GJ, Sekeres MA, Andreeff M, Kantarjian HM and Garcia-Manero G. Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome. Blood. 2017 Dec; 130(Suppl 1):4265.

67. Burger JA, Sivina M, Ferrajoli A, Jain N, Kim E, Kadia T, Estrov Z, Nogueras González G, Huang X, Ohanian M. Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2017 Dec; 130(Suppl 1):427.

68. Rausch CR, DiNardo CD, Kadia T, Takahashi K, Jain N, Benton CB, AThompson P, Ohanian M, Covert W, Mace M, Marx K, Pemmaraju N, Daver N, Jabbour EJ, Cortes JE, Garcia-Manero G, Ravandi F, Konopleva M and Kantarjian HM. Results of Off-

Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies. Blood. 2017 Dec; 130(Suppl 1):1356.

69. Boddu P, Gurguis C, Cortes JE, Akosile M, Ravandi F, Sanford D, Brandt M, Maduike R, Kadia T, Kantarjian HM and Borthakur G. Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood. 2017 Dec; 130(Suppl 1):27.

70. Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U and Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood. 2017 Dec; 130(Suppl 1):256.

71. Jain P, Kanagal-Shamanna R, Kantarjian HM, F Anthony San Lucas F. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML. Blood. 2017 Dec; 130(Suppl 1).

72. Patnaik MM, Alfonso A, Yalniz F, **Kadia TM**, Vallapureddy R, Jabbour E, Lasho TL, Hanson CA, Kantarjian HM, Ayalew Tefferi and Garcia-Manero G. Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases. Blood. 2017 Dec; 130(Suppl 1):2964.

73. Jain N, Jabbour EJ, McKay PZ, Ravandi F, Takahashi K, Kadia T, Wierda WG, Rytting ME, Nunez C, Patel K, Lu X, Tang G, Konoplev SN, AWang S, Han L, Thakral B, Roberts KG, Deshmukh A, Garris R, Jorgensen JL, AntonioCavazos, Verstovsek S, Garcia-Manero G, O'Brien SM, Cortes JE, Mullighan CG, Kantarjian HM and Konopleva M. Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial. Blood. 2017 Dec; 130(Suppl 1):1322.

74. Pierola AA, Assi R, Devendra KC, Abaza Y, Zahr AA, Chamoun K, GuillermoMontalban-Bravo, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, PPatel K, Futreal A, Pierce S, Kantarjian HM and Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood. 2017 Dec; 130(Suppl 1):3852.

75. Sasaki K, Jabbour EJ, Khouri M, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Short NJ, Issa GC, Kadia T, Jones E, Garris R, Cortes JE, Susan MO'Brien and Kantarjian HM. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood. 2017 Dec; 130(Suppl 1):2554.

76. Boddu P, Kantarjian HM, Ravandi F, Jabbour EJ, Daver N, Pemmaraju N, DiNardo CD, Verstovsek S, Alvarado Y, Borthakur G, Jain N, Konopleva M, BBenton C, Slack R, Patel KP, Garcia-Manero G, Cortes JE, Kadia T. Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and Cytarabine. Blood. 2017 Dec; 130(Suppl 1):3898.

77. Morita K, Wang F, Patel K, Bueso-Ramos C, Issa GC, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes JE, Garcia-Manero G, Jabbour EJ, Futreal A, Kantarjian HM and Takahashi K. Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia. Blood. 2017 Dec; 130(Suppl 1):2667.

78. Assi R, Benton CB, Rawi AA, Chamoun K, Wang F, Pierce S, Patel KP, Hamilton BK, DiNardo CD, Garcia-Manero G, Kantarjian HM, Kadia T, SrdanVerstovsek and Andreeff M. JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition. Blood. 2017 Dec; 130(suppl 1):1381.

79. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, Devendra KC, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M and Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood. 2017 Dec; 130(Suppl 1):305.

80. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J and Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 Dec; 130(Suppl 1):1275-1283.

81. Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gaisor Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE and Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood. 2017 Dec; 130(Suppl 1):2577.

82. Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, MarinaKonopleva, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, Susan MO'Brien and Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood. 2017 Dec; 130(Suppl 1):3876.

83. Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Estrov Z, Bose P, SherryPierce, Garris R, O'Brien SM and Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 2017 Dec; 130(Suppl 1):1434.

84. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Khoury JD, Jorgensen JL, Alvarado Y, Sasaki K, MarinaKonopleva, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WG, Estrov Z, Kornblau S, DiNardo CD, Ferrajoli A, Jacob J, Manzoor A, Garris R, O'Brien SM and Jabbour EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood. 2017 Dec; 130(Suppl 1):2576.

85. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, JamesAllison, Padmanee Sharma and Kantarjian HM. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML. Blood. 2017 Dec; 130(Suppl 1):1345.

86. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 Dec; 130(Suppl 1):2584-2587.

87. Naqvi K, Bravo GM, Pierola AA, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, NavalDaver, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, González GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood. 2017 Dec; 130(Suppl 1):4258.

88. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, PadmaneeSharma, Pierce S, Brandt M, Pike A, Cortes JE and Kantarjian HM. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 2017 Dec; 130(Suppl 1):815.

89. Borthakur G, Kantarjian HM, DiNardo CD, Daver N, Jabbour EJ, Kadia T, Garcia-Manero G, Ravandi F, Pemmaraju N, Konopleva M, Ohanian M, Wierda WG, Jain N, Xiao L, Mukherjee P, Brandt M and Cortes JE. Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. Blood. 2017 Dec; 130(Suppl 1):892.

90. Ghorab A, Preetesh J, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, SrdanVerstovsek, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood. 2017 Dec; 130(Suppl 1):2868.

91. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, **Kadia TM**, Konopleva M, DiNardo CD, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. Blood. 2017 Dec; 130(Suppl 1):3209.

92. Daver N, Boddu P, Garcia-Manero G, Ravandi F, Jabbour EJ, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Kadia T, Jain N, Pierce S, Flores W, Kornblau S, Hussain N, Ning J, González GN, Basu S, Cortes JE, PadmaneeSharma and Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. Blood. 2017 Dec; 130(Suppl 1):2634.

93. Issa GC, Kantarjian HM, Gonzalez NG, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E and Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood. 2017 Dec; 130(Suppl 1):2091.

94. Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM and Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood. 2017 Dec; 130(Suppl 1):1379.

95. Assi R, Kantarjian HM, Cortes JE, Kadia T, Pemmaraju N, Jabbour EJ, Jain N, Daver N, Uehara T, Takashi Owa and Borthakur G. Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood. 2017 Dec; 130(Suppl 1):1380.

96. Khan M, Kantarjian HM, Ning J, Akosile M, Li W, Borthakur G, Jain N, DiNardo CD, Wierda WG, Ravandi F, Garcia-Manero G, Konopleva M, Kadia T, Pemmaraju N, Thompson PA, Daver N, Jabbour EJ and Cortes JE. Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia. Blood. 2017 Dec; 130(Suppl 1):2882.

97. Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Khoury JD, Ravandi F, JShort N, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, Susan MO'Brien and Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 2017 Dec; 130(Suppl 1):1435.

98. Assi R, Kantarjian HM, Khouri R, Ravandi F, Kebriaei P, Short NJ, Thomas DA, Garcia-Manero G, Champlin RE, Kadia T, Cortes JE, Jain N, Konopleva M, ZeevEstrov, Takahashi K, Sasaki K, Jacob J, Manzoor A, Garris R, O'Brien SM and Jabbour EJ. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 2017 Dec; 130(Suppl 1):2597.

99. Swaminathan M, Kantarjian HM, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo CD, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour EJ, Wierda WG, Ravandi F, Pinsoy MR and Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood. 2017 Dec; 130(Suppl 1):723.

100. Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Borthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo CD, SherryPierce, Wierda WG, Kornblau S, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right? Blood. 2017 Dec; 130(Suppl 1):4693.

101. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ and Wierda WG. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood. 2017 Dec; 130(Suppl 1):429.

102. Pemmaraju N, Boddu P, Kantarjian HM, Ravandi F, Lima MD, Champlin RE, Rondon G, Kadia T, Jabbour EJ, Garcia-Manero G, Muzaffar HQazilbash CJA. Outcomes after Third Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Acute and Chronic Leukemias. Blood. 2017 Dec; 130(Suppl 1):5551.

103. Ohanian M, Kantarjian HM, Borthakur G, **Kadia TM**, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood. 2016 Dec; 128(22):2744.

104. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, **Kadia TM**, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff M. Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood. 2016 Dec; 128(22):2952.

105. Aoki E, Jain P, Ferrajoli A, Estrov Z, Keating M, O'Brien SM, Wierda WG, Jain N, Thompson PA, Jabbour E, Pierce S, Hosing C, Kantarjian HM, Ravandi F, **Kadia TM**. Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience. Blood. 2016 Dec; 129(22):2997.

106. Jain P, Kantarjian HM, Jabbour EJ, Gonzalez GN, Garcia-Manero G, Kanagal-Shamanna R, Patel KP, Hu S, DellaSala SE, Pierce S, Sasaki K, Konopleva M, Wierda WG, Daver N, **Kadia TM**, Borthakur G, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood. 2016 Dec; 128(22):1220.

107. Borthakur G, Ishizawa J, DiNardo CD, **Kadia TM**, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Blood. 2016 Dec; 128(22):3997.

108. Jabbour EJ, Kantarjian HM, Sasaki K, **Kadia TM**, Ravandi F, Cortes JE, Khoury JD, Patel K, Bueso-Ramos CE, Daver NG, Borthakur G, Jain N, DiNardo CD, Konopleva M, Verstovsek S, Pemmaraju N, Estrov Z, Miller D, Maduike R, Faderl S, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood. 2016 Dec; 128(22):3166.

109. Jain P, Casteel D, Allen CE, McClain KL, Wang S, Konoplev S, Jabbour EJ, Gonzalez GN, Huang X, Miller S, Abdelall W, Tamamyan G, **Kadia TM**, Borthakur G, Estrov Z, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM, Daver N. Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. Blood. 2016 Dec; 128(22):2791.

110. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, **Kadia TM**, Garcia-Manero G, DiNardo CD, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle CK, Salinas K, Mak PY, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood. 2016 Dec; 128(22):3105.

111. Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Jr B, RL, Daver N, **Kadia TM**, Matthews J, Flores W, Somani N, Blando J, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2016 Dec; 128(22):2012.

112. Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, **Kadia TM**, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood. 2016 Dec; 128(22):1940.

113. Alhuraiji A, Kantarjian HM, Jabbour EJ, Boddu PC, Ravandi F, Borthakur G, DDiNardo C, Daver N, **Kadia TM**, Pemmaraju N, Pierce S, Garcia-Manero G, Cortes JE. Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. Blood. 2016 Dec; 128(22):3064.

114. Montalban-Bravo G, Takahashi K, Pierola AA, Wang F, Xingzhi S, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A, Kantarjian HM, Garcia-Manero G. Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. Blood. 2016 Dec; 128(22):4317.

115. Abaza Y, Jabbour EJ, Verstovsek S, Estrov Z, Ravandi F, Borthakur G, **Kadia TM**, Daver N, DiNardo CD, Bueso-Ramos CE, Hidalgo JE, Schneider H, Montalban-Bravo G, Alfonso A, Wei Y, Kantarjian HM, Garcia-Manero G. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood. 2016 Dec; 128(22)::4318.

116. Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, **Kadia TM**, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HG, Jabbour EJ. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 2016 Dec; 128(22).

117. Boddu PC, Kantarjian HM, RashidShah A, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau SM, Dellasala SE, Pierce S, Jabbour EJ, Cortes JE. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood. 2016 Dec; 128(22):3073.

118. Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, **Kadia TM**, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood. 2016 Dec; 128(22):4262.

119. Jain N, Ravandi F, Garcia-Manero G, Borthakur G, **Kadia TM**, Jabbour EJ, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Alvarado Y, Takahashi K, Benton CB, Pike A, Pierce S, Cortes JE, Kantarjian HM. Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 2016 Dec; 128(22):2817.

120. Jain P, Kantarjian HM, Ravandi F, Kanagal-Shamanna R, Khoury JD, Patel KP, Garcia-Manero G, Konopleva M, Jain N, Sasaki K, **Kadia TM**, Borthakur G, Garris R, Pierce S, Estrov Z, Wierda WG, Cortes JE, O'Brien SM, Jabbour EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood. 2016 Dec; 128(22):2779.

121. Montalban-Bravo G, Takahashi K, Wang F, Konopleva M, Xingzhi S, Gonzalez GN, Huang X, Pierola AA, Jabbour EJ, Colla S, Borthakur G, Daver N, DiNardo CD, Estrov Z, **Kadia TM**, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Chamseddine AN, Zhang J, Kantarjian HM, Patel K, Chin L, Futreal A, Garcia-Manero G. Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood. 2016 Dec; 128(22):54.

122. Montalban-Bravo G, Takahashi K, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A,

Kantarjian HM, Garcia-Manero G. STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. Blood. 2016 Dec; 128(22):3182.

123. Sasaki K, Kantarjian HM, Ravandi F, Daver N, **Kadia TM**, Khouri RB, Alvarado Y, Burger JA, Thomas DA, Garcia-Manero G, DiNardo CD, Pemmaraju N, Short NJ, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda WG, Verstovsek S, Cortes JE, Konopleva M, O'Brien SM, Jabbour EJ. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood. 2016 Dec; 128(22):2783.

124. Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, **Kadia TM**, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, aj Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood. 2016 Dec; 128(22):1975.

125. Thompson PA, Strati P, Keating M, O'Brien SM, Ferrajoli A, Burger JA, Jorgensen JL, Faderl S, Estrov Z, Jain N, Kadia T, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Wierda WG. Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse. Blood. 2016 Dec; 128(22):232.

126. Ohanian M, Garcia-Manero G, Jabbour EJ, Daver N, Borthakur G, **Kadia TM**, Brandt M, Pierce S, Burger J, Richie MA, Patel K, Cortes JE, Kantarjian HM, Ravandi F. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. Blood. 2016 Dec; 128(22):1611.

127. Chamoun K, Kantarjian HM, Rios MB, Assi R, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, **Kadia TM**, Pemmaraju N, Jabbour EJ, Cortes JE. CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. Blood. 2016 Dec; 128(22):1923.

128. Alfonso Pierola A, Montalban-Bravo G, Chamseddine AN, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. Blood. 2016 Dec; 128(22):4340.

129. Assi R, Kantarjian HM, Verstovsek S, Garcia-Manero G, Konopleva M, Ravandi F, DiNardo CD, **Kadia TM**, Daver N, Jabbour EJ, Gborogen RA, Chamoun K, Wierda WG, Borthakur G, Cortes JE. CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. Blood. 2016 Dec; 128(22):4047.

130. Sasaki K, Jabbour EJ, O'Brien SM, Ravandi F, Thomas DA, **Kadia TM**, Garcia-Manero G, Burger JA, Pemmaraju N, Alvarado Y, Daver NG, Jain N, Konopleva M, Champlin RE, Khouri IF, Kebriaei P, Marin D, DiNardo CD, Estrov Z, Takahashi K, Short NJ, Khouri MR, Jacob J, Garris R, Cortes JE, hm K. Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood. 2016 Dec; 128(22):1606.

131. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar JK, Pemmaraju N, Borthakur G, **Kadia TM**, Konopleva M, Kantarjian HM, Cortes JE, Hearn KP, Reyes SR, Bueso-Ramos CE, Garcia-Manero G. Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation. Blood. 2016 Dec; 128(22):3191.

132. Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, **Kadia TM**, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood. 2016 Dec; 128(22):1612.

133. Montalban-Bravo G, Huang X, Jabbour EJ, Borthakur G, DiNardo CD, Pemmaraju N, Cortes JE, Verstovsek S, **Kadia TM**, Daver NG, Wierda WG, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso Pierola A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos CE, Pierce S, Estey EH, Bohannan ZS, Kantarjian HM, Garcia-Manero G. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. Blood. 2016 Dec; 128(22):1999.

134. Sasaki K, Jabbour EJ, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Khouri RB, Yilmaz M, **Kadia TM**, Short NJ, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis TV, Cortes JE, O'Brien SM, Kantarjian HM. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood. 2016 Dec; 128(22):757.

135. Abaza Y, Kantarjian HM, Jabbour EJ, Thomas DA, **Kadia TM**, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood. 2016 Dec; 128(22):177.

136. Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, **Kadia TM**, Kornblau SM, Ohanian M, Alfonso Pierola A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero GM. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). bLOOD. 2016 Dec; 128(22):346.

137. Yohannan Sam P, Ahaneku H, Nogueras-Gonzalez GM, Jabbour E, Garcia-Manero G, Borthakur G, Wierda WG, Daver N, Kadia T, Burger J, Pierce S, DiNardo CD, Ravandi F, Kantarjian HM, Cortes JE. Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood. 2016 Dec; 128(22):1919.

138. Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, **Kadia TM**, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HM, Jabbour EJ. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 2016 Dec; 128(22):1067.

139. Short NJ, Kantarjian HM, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang S, Thomas DA, Khoury JD, Champlin RE, Khouri IF, Kebriaei P, Marin D, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, **Kadia TM**, Jain N, Konopleva M, Garris R, Jabbour EJ. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood. 2016 Dec; 128(22):2916.

140. Alfonso Pierola A, Montalban-Bravo G, Takahashi K, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Pierce S, Kantarjian HM, Garcia-Manero G. Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. Blood. 2016 Dec; 128(22):111.

141. Jain P, Wang S, Kantarjian HM, Sarwari N, Patel KP, Bose P, Pierce S, **Kadia TM**, Daver N, Pemmaraju N, Cortes JE, Verstovsek S. Aleukemic Mast Cell Leukemia (aMCL) - Clinical Characteristics and Outcomes. Blood. 2016 Dec; 128(22):4255.

142. Kantarjian HM, Jabbour EJ, Garcia-Manero G, **Kadia TM**, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Zhang C, Ravandi F, Plunkett W. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. Blood. 2016 Dec; 128(22):2822.

143. Abdelall W, Kantarjian HM, Borthakur G, Garcia-Manero G, Patel KP, Jabbour EJ, Daver NG, Kadia T, Gborogen RA, Konopleva M, Ravandi F, Andreeff M, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood. 2016 Dec; 128(22):1642.

144. Montalban-Bravo G, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Patel K, Futreal A, Kantarjian HM, Takahashi K, Garcia-Manero G. Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. Blood. 2016 Dec; 128(22):51.

145. Boddu PC, Kantarjian HM, Garcia-Manero G, Verstovsek S, Ravandi F, Jabbour EJ, Takahashi K, Bhalla KN, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, **Kadia TM**. Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. Blood. 2016 Dec; 128(22):2788.

146. Benton CB, Takahashi K, Bose P, Wang F, Chen HC, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, **Kadia TM**, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian HM. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood. 2016 Dec; 128(22):597.

147. Jabbour EJ, Short NJ, Huang X, Maiti A, **Kadia TM**, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian HM, Garcia-Manero G. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood. 2016 Dec; 128(22):226.

148. Montalban-Bravo G, Alfonso Pierola A, Takahashi K, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G.

Myelodysplastic Syndromes with NPM1Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood. 2016 Dec; 128(22):3171.

149. Alfonso Pierola A, Montalban-Bravo G, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, **Kadia TM**, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. Blood. 2016 Dec; 128(22):3177.

150. Jain P, Kantarjian HM, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrajoli A, Ohanian M, Konopleva M, Naqvi K, Fitch T, Garcia-Manero G, Cortes JE, Estrov Z, **Kadia TM**. Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood. 2016 Dec; 128(22):1639.

151. **Kadia T**, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood. 2015 Dec.

152. **Kadia T**, Cortes JE, Jabbour EJ, Daver N, Pemmaraju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, Garcia-Manero G, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian HM. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood. 2015 Dec.

153. **Kadia T**, Ravandi F, Daver N, Borthakur G, Cortes JE, Jabbour E, Kornblau SM, Verstovsek S, Wierda W, Burger JA, Estrov Z, DiNardo C, Dong XQ, Pemmaraju N, Ohanian M, Takahashi K, Hendrickson S, Kantarjian H, Garcia-Manero G. Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood. 2015 Dec.

154. Khan M, Kristy B, **Kadia T**, Ferrajoli A, Alvarado Y, Borthakur G, Pemmaraju N, Konopleva M, Garcia-Manero G, DiNardo C. Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial. Blood. 2015 Dec.

155. Tamamyan G, Borthakur G, Cortes JE, Ravandi F, Jabbour E, Daver N, Pemmaraju N, Ohanian M, Kolomansky A, Todisco G, Shi C, Pierce S, S Andrew Peng S, Konopleva M, Kantarjian HM, **Kadia T**. Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission. Blood. 2015 Dec.

156. Jabbour, E, Sasaki, K, Daver, N, Pemmaraju, N, Jain, N, **Kadia**, **TDiNardo**, C, Tuttle, C, Borthakur, G, Konopleva, M, Faderl, S, O'Brien, S, Cortes, J, Kantarjian, H, Garcia-Manero, G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. 2014 Dec.

157. Jabbour, E, Kantarjian, H, Thomas, D, Sasaki, K, Garcia-Manero, G, Garris, R, Cortes, J, **Kadia**, **T**, Ravandi, F, Verstovsek, S, O'Brien, S. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood. 2014 Dec.

158. Kadia, T, Borthakur, G, Ferrajoli, A, Daver, N, Jabbour, E, Pemmaraju, N, Verstovsek, S, Burger, J, Wierda, W, Konopleva, M, DiNardo, C, Jain, N, Brandt, M, Pierce, S, Garcia-Manero, G, Cortes, J, Kantarjian, H. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood. 2014 Dec.

159. Jabbour, E, O'Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, **Kadia**, **T**, Jain, N, York, S, Garris, R, Cortes, J, Kantarjian, H. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood. 2014 Dec.

160. Jabbour, E, O'Brien, S, Sasaki, K, Huang, X, Thomas, D, Rytting, M, Garcia-Manero, G, Cortes, J, Pierce, S, **Kadia**, **T**, Kantarjian, H. Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood. 2014 Dec.

161. Jabbour, E, Kantarjian, H, Thomas, D, Sasaki, K, Ravandi, F, Cortes, J, Pemmaraju, N, **Kadia**, **T**, Garris, R, Garcia-Manero, G, Borthakur, G, Wierda, O'Brien, S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood. 2014 Dec.

162. Jabbour, E, Sasaki, K, Daver, N, Pemmaraju, N, DiNardo, C, **Kadia**, **T**, Miller, D, Sukholutsky, V, Huang, X, Borthakur, G, Estrov, Z, Kantarjian, H Garcia-Manero H, G, . Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood. 2014 Dec.

163. Kadia, T, Thomas, X, Dmoszynska, A, Wierzbowska A, Minden M, Arthur C, Porre PD, Xiu L, Doyle M, Bussolari J, Kantarjian H. Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts. 2014 Sep.

164. Jabbour, E, Kantarjian HM, Ning J, Garcia-Manero G, **Kadia**, **T**, O'Brien S, Cortes JE, Hoehn D, Bryan J, Ravandi F, Verstovsek, S. Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). Blood. 2013 Dec.

165. Jabbour, E, Hagop K, Thomas D, Garcia-Manero G, Hoehn D, Garris R, Faderl SH, Cortes JE, **Kadia**, T, **Ravandi F**, Verstovsek S, O'Brien S. Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood. 2013 Dec.

166. Kadia, T, Daver N, Virani F, Jabbour E, Pierce S, Pemmaraju N, Quintas-Cardama A, Borthakur G, O'Brien S, Kantarjian HM, Cortes JE. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. Blood. 2013 Dec.

167. Kadia, T, Borthakur G, Ferrajoli A, Jain P, Jabbour E, Verstovsek S, Pemmaraju N, Faderl S, Ravandi F, Konopleva M, Tuttle C, Brandt M, Wang X, Garcia-Manero G, Kantarjian HM, Cortes JE. Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood. 2013 Dec.

168. Nazha, A, Kantarjian HM, Jabbour E, DiNardo CD, Borthakur G, Daver NG, Faderl SH, Ning J, Qiao W, Ravandi F, **Kadia**, **T**, Pierce SR, Cortes JE, Garcia-Manero G. Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. Blood. 2013 Dec.

169. Kadia, T, Cortes JE, Thomas D, Ravandi F, Pemmaraju N, Daver N, Quintás-Cardama A, Baccus M, Garris R, Jabbour EJ, Kantarjian HM, Borthakur AG. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2012 Nov.

170. Takahashi K, Kantarjian HM, Ghanem H, Ravandi F, Cortes JE, **Kadia**, **T Susan O'Brien T**, Pierce SA, Jain N, Garcia-Manero G, J Jabbour AE. Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure. Blood. 2012 Nov.

171. Ravandi F, Kadia, T, Borthakur G, Wierda WG, Goldberg SL, Wetzler M, Venugopal P, Seiter K, Chiao J, Kantarjian HM. Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood. 2012 Nov.

172. H Ghanem H, H Kantarjian H, G Garcia-Manero G, F Ravandi F, S Faderl S, J E Cortes J, A Reyes A, S M O'Brien S, G Borthakur G, **Kadia TM**, J A Burger J, M Konopleva M, E Jabbour E. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO. 2011 Jun; 29(15S).

173. A Al-Ameri A, D A Thomas D, F Ravandi F, S M O'Brien S, H Kantarjian H, G Borthakur G, **Kadia TM**, M Kelly M, R Garris R, Faderl AS. Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). JCO. 2011 Jun.

174. A Quintas-Cardama A, J E Cortes J, E Jabbour E, S M O'Brien S, G Garcia-Manero G, J Shan J, F Ravandi F, S Faderl S, **Kadia TM**, G Borthakur G, H Kantarjian H. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. JCO. 2011 Jun; 29(15S).

175. G Borthakur G, L Popplewell L, M H Kirschbaum M, J M Foran J, **Kadia TM**, E Jabbour E, M Boyiadzis M, A Verma A, R B Walter R, P S Wissel P, L Xu L, J W Bauman J, J Z Zhu J, J Mazumdar J, M Baccus M, J M Connor J, J E Cortes J, H Kantarjian H. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. JCO. 2011 Jun; 29(15).

176. Kadia, T, G Garcia-Manero G, H Kantarjian H, N Pemmaraju N, K Stein K, A Teng A, J E Cortes J. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. JCO. 2011 Jun; 29(15S).

177. E Jabbour E, S M O'Brien S, D A Thomas D, F Ravandi F, S York S, M Kwari M, S Faderl S, **Kadia**, **T**, C Wilson C, R Tarnai R, A S Advani A, G Garcia-Manero G, J E Cortes J, H Kantarjian H. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). JCO. 2011 Jun; 29(15S).

178. F Ravandi F, S Faderl S, J E Cortes J, G Garcia-Manero G, E Jabbour E, P A Boone P, **Kadia TM**, G Borthakur G, W G Wierda W, J H Chiao J, H Kantarjian H. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. JCO. 2011 Jun; 29(15S).

179. S Faderl S, F Ravandi Kashani F, G Borthakur G, **Kadia TM**, E Jabbour E, G Garcia-Manero G, M Brandt M, S Pierce S, H Kantarjian H. Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison. JCO. 2010 Jun; 28(15).

180. A Fullmer A, G Borthakur G, **Kadia TM**, G Garcia-Manero G, E Jabbour E. Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine. JCO. 2010 Jun; 28(15).

181. Y Chen Y, H Kantarjian H, G Garcia-Manero G, Z Estrov Z, M Konopleva M, E Jabbour E, **Kadia TM**, B Williams B, S George S, G Borthakur G. Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO. 2010 Jun; 28(15).

182. N Pemmaraju N, H Kantarjian H, S Faderl S, G Garcia-Manero G, **Kadia TM**, G Borthakur G, J E Cortes J, F Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). JCO. 2010 Jun; 28(15).

183. G Borthakur G, E Jabbour E, X Wang X, J E Cortes J, F Ravandi Kashani F, **Kadia TM**, J Bass J, M Brandt M, H Kantarjian H. Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). JCO. 2010 Jun; 28(15).

184. B Pro B, G F Perini G, L Feng L, J E Romaguera J, M A Rodriguez M, P McLaughlin P, F B Hagemeister F, L Fayad L, **T M Kadia T**. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. JCO. 2010 Jun; 28(15).

185. A Al-Kali A, S N Konoplev S, E Lin E, **Kadia TM**, S Faderl S, F Ravandi Kashani F, M Ayoubi M, M Brandt M, H Kantarjian H, G Borthakur G. Hypocellular acute myeloid leukemia: Better or worse prognosis. JCO. 2010 Jun; 28(15).

186. Kadia, T, F Ravandi Kashani F, S M O'Brien S, J E Cortes J, E Jabbour E, G Borthakur G, S Faderl S, S Pierce S, M Brandt M, Kantarjian AH. Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). JCO. 2010 Jun; 28(15).

187. Ayoubi M Thomas D, Kantarjian H, O'Brien S, Ravandi F, Garcia-Manero G, Verstovsek S, Rytting M, Borthakur G, **Kadia TM**, Kornblau S, Andreeff M, Feliu J, Faderl S. Augmented Hyper - CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper - CVAD Using Dose - Intense Vincristine, Dexamethasone, and Pegaspargase. Blood. 2009 Nov; 114(22):802.

188. Jabbour E, Kantarjian H, Parikh A, Thomas D, **Kadia TM**, Garcia-Manero G, Borthakur G, Pierce S, Brandt M, Cortes J, Verstovsek S. Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF). Blood. 2009 Nov; 114(22):1133.

189. Santos F, Schlette E, Kantarjian H, Sargent R, Garcia-Manero G, Verstovsek S, **Kadia TM**, Jabbour E, Pierce S, Borthakur G. Myelodysplastic Syndrome with Fibrosis: Experience of a Single Institution with 139 Patients. Blood. 2009 Nov; 114(22):1085.

190. Santos F, Kantarjian H, **TM K**, Bivins C, O' Brien S, Ravandi F, Cortes J, Garcia-Manero G, Faderl S, Pierce S, Jabbour E. High Prevalence of FLT3 - ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Central Nervous System (CNS) Relapse. Blood. 2009 Nov; 114(22):423.

191. Badoux X, Keating M, O'Brien S, Ferrajoli A, Burger J, Faderl S, Garcia-Manero G, **Kadia TM**, Abruzzo L, Wierda W. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood. 2009 Nov; 114(22):513.

192. **Kadia TM**, Kornblau S, Kantarjian H, Faderl S, Jones D, Garcia-Manero G, Borthakur G, Koller C, Verstovsek S, Peirce S, Cortes J, Ravandi F. Clinical characterization and Proteomic Consequences of mutated Ras in Acute Myeloid Leukemia. Blood. 2009 Nov; 114(22):139.

193. Chen Y, Cortes J, Lin E, Ravandi F, Faderl S, **Kadia TM**, Kantarjian H, Borthakur G. Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations. Blood. 2009 Nov; 114(22):820.

194. Badoux X, Keating M, O' Brien S, **Kadia TM**, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger J, Wierda W. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 2009 Nov; 114(22):1332.

195. **Kadia TM**, Estrov Z, Ravandi F, Koller C, Borthakur G, Jabbour E, Faderl S, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated on Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid. Blood. 2009 Nov; 114(22):818.

196. Rytting M, Thomas D, Franklin A, Jabbour E, Wierda W, Faderl S, Wells R, **Kadia TM**, Ravandi F, Ferrajoli A, Cortes J, O' Brien S, Kantarjian H. Pediatric - Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. Blood. 2009 Nov; 114(22):804.

197. Parikh S, Kantarjian H, Garcia-Manero G, Jabbour E, **Kadia TM**, Ravandi F, Ferrajoli A, Estrov Z, Feliu J, Faderl S. Clofarabine Plus Low - Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low - Dose Cytarabine Alternating with

Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) >/60 Years (yrs). Blood. 2009 Nov; 114(22):813.

198. Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, Thomas D, **Kadia TM**, Williams B, George S, Kantarjian H. A Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients. Blood. 2009 Nov; 114(22):435.

199. Kim H, Jabbour E, **Kadia TM**, Borthakur G, Pierce S, Shan J, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Garcia-Manero G. A Prognostic Model of Therapy - Related Myelodysplastic syndrome. Blood. 2009 Nov; 114(22):1460.

200. Batty N, Badoux X, Keating M, Lin E, Lerner S, O'Brien S, Ferrajoli A, **Kadia TM**, Burger J, Faderl S, Wierda W. Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic leukemia (CLL). Blood. 2009 Nov; 114(22):1339.

201. Garcia-Manero G, Khoury J, Borthakur G, Ravandi F, **Kadia TM**, Estrov Z, Jabbour E, Foudray MC, Arellano M, Langston A, Bryan B, Rush S, Freeman B, Simmons H, Ptaszynski, Kantarjian H. A Phase 1 Dose - Escalation Study of the Novel KSP Inhibitor ARRY -520 In Advanced Leukemias. Blood. 2009 Nov; 114(22):808.

202. Garcia-Manero G, Tambaro F, Nebiyou B, Jabbour E, Ravandi F, Yang H, Borthakur G, **Kadia TM**, Cortes J, Faderl S, Konopleva M, Pierce S, Burger J, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood. 2009 Nov; 114(22):437.

203. Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger J, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, **Kadia TM**, Garcia-Manero G, Kornlau S, Andreeff M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a Modified Hyper - CV AD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 2009 Nov; 114(22):344.

204. Cortes J, O'Brien S, jones D, Jabbour E, Konopleva M, Ferrajoli A, **Kadia TM**, Borthakur G, Stigliano D, Shan J, Kantarjian H. Efficacy of Nilotinib in Patients (pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromomsome (Ph) - Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML- CP). Blood. 2009 Nov; 114(22):145.

205. Tong W, **Kadia TM**, Borthakur G, Jabbour E, Pierce S, Shan J, Cortes J, Ravandi F, Wierda W, Thomas D, Kantarjian H, Garcia-Manero G. Prognostic Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score. Blood. 2009 Nov; 114(22):1469.

206. Verma, D, Kantarjian H, Shan J, O'Brien S, Verma A, Jabbour E, Verstovsek S, **Kadia TM**, Rios M, Cortes J. Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): A Target Worth Aiming and Achieving? Blood. 2009 Nov; 114(22):209.

207. Walker JG, **Kadia TM**, Brown L, Juneja HS, De Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol. 2009 Aug.

208. Garcia -Manero G, Couriel R D, Tambaro P F, Gabrail N, Nadeem A, **Kadia TM**, Jabbour E, Borthakur G, Faderl S, Newsome W, Yang H, Chen K, Stein K, Kantrajian H. A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Time Three in patients with Lower Risk Myelodysplastic Syndrome (MDS). Blood. 2009 May; 114(22):54.

209. Yang H, **Kadia TM**, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb; 113(9):1892-8. PMID: 19109226 PMCID: PMC2651008.

210. Thompson MA, **Kadia TM**, Bekele BN, Wang M, Romaguera JE. Cyclin D1 polymorphisms as predictive and prognostic molecular markers in 90 mantle cell lymphoma patients treated with R-HyperCVAD. Poster Presentation, American Society of Hematology. 2007 Dec.

211. **Kadia TM**, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstosvek S, Newsom W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Poster Presentation, American Society of Hematology Meeting. 2007 Dec.

212. **Kadia TM**, Kantarjian H, Verstovesek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. Poster Presentation, American Society of Hematology Meeting. 2007 Dec.

213. **Kadia TM**, Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. Phase I Study of the Combination of a DNA Topoisomerase Inhibitor, Idaruicin, with the Histone Daecetylase Inhibitor Vorinostat in Advanced Leukemia. Poster Presentation, American Society of Clinical Oncology Meeting. 2007 May.

214. **Kadia TM**, Rodriguez A, Fayad L, Mclaughlin P, Pro B. Retrospective Review of Angioimmunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. American Society of Hematology Meeting. 2006 Dec.

JOURNAL ARTICLES - OTHER

1. **Kadia**, **T**. Chronic Lymphocytic Leukemia: New Insights Lead to More Refined, Individualized Treatment. Molecular Oncology. 2007 Jan.

2. **Kadia**, **T**, Jabbour E, O'Brien S. Treatment Strategies for Chronic Lymphocytic Leukemia. Oncology. 2006 Jan.

BOOK CHAPTERS

1. Kainthala, R Pemmaraju R, N Kadia T. Leukemias. In: Handbook of Targeted Therapy. United States of America: 2014.

2. Kadia T, Ravandi F. Induction Therapy in Acute Myeloid Leukemia. In: Cancer: Expert Clinical Perspective. United States of America: 2014.

CONFERENCE ABSTRACTS

1. Masarova L, Daver NG, **Kadia TM**, Pemmaraju N, Jabbour EJ, Zhou L, Pierce SA, Cortes JE, Kantarjian HM, Verstovsek S. Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study. Blood 2018 Dec; 132(Suppl 1):1764.

2. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, YesidAlvarado, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, **Kadia TM**, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 2018 Dec; 132(Suppl 1):232.

3. Rausch CR, Paul S, Montalban Bravo G, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, **Kadia TM**, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 2018 Dec; 132(Suppl 1).

4. Yalniz F, Kantarjian HM, Borthakur G, **Kadia TM**, Daver NG, Pemmaraju N, Konopleva MY, Garcia-Manero G, Takahashi K, DiNardo CD, Bose P, Andreeff M, Ravandi F, Cortes JE. Potential Predictors of Induction Failure and Complete Remission Duration inFLT3-ITD Mutated Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):3996.

5. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, AThompson P, Borthakur G, **Kadia TM**, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, Flores W, Basu S, Allison JP, Sharma P, Pierce SA, Pike A, Cortes JE, Ravandi F. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood 2018 Dec; 132(Suppl 1):905.

6. Jain N, Ferrajoli A, Basu S, Thompson PA, Burger JA, **Kadia TM**, Estrov ZE, Pemmaraju N, Lopez W, Thakral B, Khoury JD, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison JP, Keating MJ, Sharma P, Wierda WG. A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. Blood 2018 Dec; 132(Suppl 1):296.

7. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Naqvi K, Pierola AA, Yilmaz M, Short NJ, Jabbour EJ, Ravandi F, **Kadia TM**, Pierce SA, Takahashi K, DiNardo CD, Nogueras González GM, Abaza Y, Devendra KC, Chamoun K, Sakurai K, Patel KP, Cortes JE, Kantarjian HM, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):4359.

8. Sasaki K, Kantarjian HM, Short NJ, Ravandi F, Khouri M, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Jacob J, Garris RE, Yilmaz M, Thompson PA, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Jabbour EJ. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood 2018 Dec; 132(Suppl 1):34.

9. Swaminathan M, Morita K, Yuanqing Y, Wang F, Burks J, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Zhang J, Song X, DiNardo CD, Jabbour EJ, **Kadia TM**, Cortes JE, Daver NG, Pemmaraju N, Patel K, Garcia-Manero G, Kantarjian HM, Bueso-Ramos CE, Futreal A, Takahashi K. Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. Blood 2018 Dec; 132(Suppl 1):5240.

10. Chamoun K, Kantarjian HM, Naqvi K, Wang X, Garcia-Manero G, Borthakur G, Jabbour EJ, **Kadia TM**, Daver NG, DiNardo CD, Jain N, Konopleva MY, ECortes J, Ravandi F, Yilmaz M. Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). Blood 2018 Dec; 132(Suppl 1).

11. Assi R, Boddu P, **Kadia TM**, Estrov ZE, Garcia-Manero G, Ravandi F, Jabbour EJ, Takahashi K, Konopleva MY, Andreeff M, Zahr AA, DiNardo CD, Borthakur G, Jain N, Pemmaraju N, Yilmaz ME, Short NJ, Ning J, Pierce SA, Wierda WG, Cortes JE, Kantarjian HM, Daver NG. Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. Blood 2018 Dec; 132(Suppl 1):3689.

12. Fiskus W, Mill CP, Soldi R, Han R, Saenz DT, Nowak AJ, Sun B, Saenz DN, DiNardo CD, Borthakur G, **Kadia TM**, Jin W, Ganesh T, Rao V, Khoury JD, Sharma S, Bhalla KN. Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells. Blood 2018 Dec; 132(Suppl 1):3930.

13. Morita K, Wang F, Makishima H, Yan Y, Yoshizato T, Yoshida K, PPrzychodzen B, Patel K, Bueso-Ramos CE, Gumbs C, Little L, Tippen S, Zhang J, Song X, **Kadia TM**, Daver NG, Pemmaraju N, DiNardo CD, Ravandi F, SrdanVerstovsek, Jabbour EJ, Cortes JE, Kantarjian HM, Garcia-Manero G, PMaciejewski J, Ogawa S, Futreal P, Takahashi K. Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. Blood 2018 Dec; 132(Suppl 1):1801.

14. Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, **Kadia TM**, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 2018 Dec; 132(Suppl 1):1831.

15. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2018 Dec; 132(Suppl 1).

16. Alfayez M, Kantarjian HM, **Kadia TM**, Garcia-Manero G, Ravandi F, Borthakur G, DiNardo CD, Rios MB, Jabbour EJ, Cortes JE. Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. Blood 2018 Dec; 132(Suppl 1):5447.

17. DiNardo CD, Albitar M, **Kadia TM**, Naqvi K, Vaughan K, Cavazos, A, Pierce SA, Takahashi K, Kornblau SM, Ravandi F, Cortes JE, Kantarjian HM, Konopleva MY. Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study. Blood 2018 Dec; 132(Suppl 1).

18. Mill CP, Cai T, Fiskus W, Borthakur G, Kornblau SM, **Kadia TM**, DiNardo CD, Nowak AJ, Saenz DT, Saenz DN, Sun B, Ganesh T, WendyJin, Rao V, Khoury JD, Shen Y, Konopleva MY, Bhalla KN. Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. Blood 2018 Dec; 132(Suppl 1):1351.

19. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, YesidAlvarado, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, KiranNaqvi, Cortes JE, **Kadia TM**, Konopleva MY, Colla S, Yang H, Rausch CR, YvonneGasior, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 2018 Dec; 132(Suppl 1):465.

20. Alfayez M, Kantarjian HM, Ravandi F, Garcia-Manero G, Konopleva MY, Daver NG, DiNardo CD, Borthakur G, Bose P, Andreeff M, Alvarado Y, Yilmaz ME, Pemmaraju N, Kornblau SM, Estrov ZE, Benton CB, Takahashi K, Naqvi K, Slack R, Islam R, Jabbour EJ, Cortes JE, **Kadia TM**. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1).

21. Kanagal-Shamanna R, Sasaki K, Bravo GM, Benton CB, Jabbour EJ, Borthakur G, **Kadia TM**, Bueso-Ramos CE, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):1820.

22. Major CK, Kantarjian HM, Borthakur G, **Kadia TM**, Pemmaraju N, JShort N, Daver NG, Jabbour EJ, Champlin RE, Garcia-Manero G, Konopleva MY, Andreeff M, Kornblau SM, Wierda WG, Pierce SA, Ravandi F, Cortes JE. Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood 2018 Dec; 132(Suppl 1):3976.

23. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Alvarado Y, **Kadia TM**, Kantarjian HM, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood 2018 Dec; 132(Suppl 1):2667.

24. Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, EEstrov Z, **Kadia TM**, Takahashi K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 2018 Dec; 132(Suppl 1):695.

25. Yalniz F, Kantarjian HM, **Kadia TM**, Garcia-Manero G, Patel K, Loghavi S, KojiSasaki, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 2018 Dec; 132(Suppl 1):3983.

26. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, F-Kashani R, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, **Kadia TM**, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 2018 Dec; 132(Suppl 1):1664-1674.

27. Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, BBenton C, **Kadia TM**, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, LuciaMasarova, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos, A, Ma H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2018 Dec; 132(Suppl 1):286.

28. Bose P, McCue D, Wiederhold NP, **Kadia TM**, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 2018 Dec; 132(Suppl 1).

29. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, **Kadia TM**, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 2018 Dec; 132(Suppl 1).

30. Aboudalle I, Kantarjian HM, Short NJ, Konopleva MY, Jain N, Garcia-Manero G, Garris RE, Qiao W, Cortes JE, O'Brien SM, Kebriaei P, **Kadia TM**, Jabbour EJ, Ravandi F. Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. Blood 2018 Dec; 132(Suppl 1):2659.

31. Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Kebriaei P, Huang X, ERytting M, Jain N, Konopleva MY, Garcia-Manero G, Champlin RE, **Kadia TM**, ECortes J, Estrov ZE, Takahashi K, Mace M, Khouri M, Nasnas P, Jacob J, EGarris R, Jabbour EJ. Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 2018 Dec; 132(Suppl 1):553.

32. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Estrov ZE, Garris RE, Khouri M, Nasnas P, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood 2018 Dec; 132(Suppl 1):2664.

33. Alfayez M, Kantarjian HM, Short NJ, Assi R, Khouri M, Ravandi F, Paul S, Rausch CR, Nasnas P, Borthakur G, DiNardo CD, **Kadia TM**, Daver NG, Garcia-Manero G, Naqvi K, Bose P, O'Brien SM, Cortes JE, Jabbour EJ. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood 2018 Dec; 132(Suppl 1):2702.

34. **Kadia TM**, Konopleva MY, Garcia-Manero G, Benton CB, Wierda WG, Bose P, Yilmaz ME, Jabbour EJ, Kornblau SM, Bhalla KN, Pemmaraju N, Jain N, Malla R, Borthakur G, Cortes JE, Ravandi F, Kantarjian HM. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood 2018 Dec; 132(Suppl 1):4057.

35. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, **Kadia TM**, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 2018 Dec; 132(Suppl 1):36.

36. Saenz DT, Fiskus W, Manshouri T, Saenz DN, Soldi R, Sun B, PeterMill C, Nowak AJ, Kornblau SM, Bose P, **Kadia TM**, DiNardo CD, LuciaMasarova, Horrigan S, Khoury JD, Sharma S, Verstovsek S, Bhalla KN. Novel BET Protein Degrader-Based

Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2-MYC Axis. Blood 2018 Dec; 132(Suppl 1):177.

37. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, **Kadia TM**, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 2018 Dec; 132(Suppl 1):84.

38. Wang F, Morita K, DiNardo CD, Patel K, MacBeth K, Tosolini A, Frattini MG, Matthews J, Little L, Gumbs C, Tippen S, Song X, Zhang J, Thompson E, **Kadia TM**, Garcia-Manero G, Jabbour EJ, Ravandi F, Konopleva MY, Kantarjian HM, Futreal A, Takahashi K. Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance. Blood 2018 Dec; 132(Suppl 1):441.

39. Daver NG, Assi R, Kantarjian HM, Cortes JE, Ravandi F, Konopleva MY, MKadia T, Borthakur G, Jabbour EJ, DiNardo CD, Velasquez M, Kelly M, Ning J, Nogueras González GM, Pierce SA, Gombos D, Estrov ZE, Kornblau SM, Zhang W, Andreeff M. Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). Blood 2018 Dec; 132(Suppl 1):1441.

40. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, **Kadia TM**, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 2018 Dec; 132(Suppl 1).

41. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, **Kadia TM**, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood 2018 Dec; 132(suppl 1):2791.

42. Swaminathan M, Stavrou N, Antzoulatos S, Albitar M, Patel K, Cortes JE, DiNardo CD, **Kadia TM**, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Borthakur G. RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):5113.

43. Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, **Kadia TM**, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Pierce SA, Alvarado Y, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Nogueras González GM, Kornblau SM, MansourAlfayez, Matthews J, Flores W, Blando J, Allison JP, Sharma P, Kantarjian HM. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood 2018 Dec; 132(Suppl 1):906.

44. Ravandi F, Pierce SA, Garcia-Manero G, **Kadia TM**, Jabbour EJ, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes JE, Kim C, AKelsh M, Katz AJ, Williams R, Yang Z, Mehta B, Kantarjian HM. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):3985.

45. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, **Kadia TM**, Garcia-Manero G, DiNardo CD, Bose P, Daver NG, Konopleva MY, Ohanian MN, Pierce SA, Zhou L, Estrov ZE, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour EJ, Verstovsek S. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 2018 Dec; 132(Suppl 1):687.

46. Tallis E, Benton CB, Khan A, Assi R, DiNardo CD, Hornbaker MJ, Major CK, Boddu P, Kanagal-Shamanna R, Patel KP, Daver NG, Takahashi K, Montalban-Bravo G, **Kadia TM**, Konopleva MY, Andreeff M, Kantarjian HM, Garcia-Manero G. Diverse Landscape of TET2 Variants in MDS and AML. Blood 2018 Dec; 132(Suppl 1).

47. Aboudalle I, Kantarjian HM, Ravandi F, Jabbour EJ, Daver NG, Estrov ZE, MichaelAndreeff, Ferrajoli A, DiNardo CD, Pemmaraju N, Naqvi K, Jain N, GwenPelletier S, Garcia-Manero G, Cortes JE, **Kadia TM**. Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. Blood 2018 Dec; 132(Suppl 1):2714.

48. Masarova L, Cortes JE, Patel KP, O'Brien SM, Nogueras González GM, Konopleva MY, Verstovsek S, Garcia-Manero G, Ferrajoli A, **Kadia TM**, Ravandi F, Borthakur G, Dellasala SE, Jabbour EJ, Kantarjian HM. Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood 2018 Dec; 132(Suppl 1):3011.

49. Roman D, Kantarjian HM, Cortes JE, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Daver NG, Pemmaraju N, **Kadia TM**, Kornblau SM, Bose P, Andreeff M, Freireich EJ, Ravandi F, Aung FM. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood 2018 Dec; 132(Suppl 1):2544.

50. Tallis E, Kantarjian HM, Major CK, Vazquez M, Borthakur G, Bose P, Ravandi F, Garcia-Manero G, **Kadia TM**, Wierda WG, Ferrajoli A, Pemmaraju N, Daver NG, DiNardo CD, Konopleva MY, Kornblau SM, Champlin RE, Jabbour EJ, Pierce SA, Cortes JE. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKI. Blood 2018 Dec; 132(Suppl 1):2702.

51. Aboudalle I, Kantarjian HM, Ohanian MN, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, **Kadia TM**, Ravandi F, Cortes JE. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood 2018 Dec; 132(Suppl 1):2715.

52. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, **Kadia TM**, Konopleva MY, Jain N, Issa GC, Jeanis V, Alvarez J, Khouri M, Nasnas P, Garris RE, Wierda WG, Thompson PA, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 2018 Dec; 132(Suppl 1):2695.

53. Montalban Bravo G, Kanagal-Shamanna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, **Kadia TM**, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, EBueso-Ramos C, Patel K, Kantarjian HM, Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood 2018 Dec; 132(Suppl 1):1514.

54. Swaminathan M, Kantarjian HM, Sasaki K, Ravandi F, Borthakur G, **Kadia TM**, Garcia-Manero G, DiNardo CD, Konopleva MY, Estrov ZE, Pemmaraju N, Daver NG, Wierda WG, Ferrajoli A, Pierce SA, Dellasala MDE, Jabbour EJ, Cortes JE. Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. Blood 2018 Dec; 132(Suppl 1):3013.

55. Rampal RK, Verstovsek S, Devlin SM, Stein EM, **Kadia TM**, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial results of a Phase II Study. Blood 2018 Dec; 132(Suppl 1):354.

56. Alfayez M, Kantarjian HM, Ravandi F, Konopleva MY, Garcia-Manero G, MKadia T, Jabbour EJ, Borthakur G, DiNardo CD, Estrov ZE, Pemmaraju N, Pierce SA, Yilmaz ME, Short NJ, Takahashi K, Assi. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood 2018 Dec; 132(Suppl 1):663.

57. Ghorab A, Patel K, Cortes JE, Chihara D, Price A, **Kadia TM**, Ravandi F, Pemmaraju N, Daver NG, Dinardo CD, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation. J Clin Oncol 2018 Jun; 36(Suppl; abstr 7069).

58. Issa GC, Kantarjian HM, Wang F, González GN, Borthakur G, Tang G, Bueso-Ramos CE, Kanagal-Shamanna R, Hidalgo Lopez JE, Zhao C, Coyle M, Takahashi K, Preetesh J, Ravandi F, Kadia T, Garcia-Manero G, Jabbour EJ, Futreal A, Cortes JE. Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML. Blood 2017 Dec; 130(Suppl 1):47.

59. Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, MarinaKonopleva, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, MO'Brien S, Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 2017 Dec; 130(Suppl 1):3876.

60. Swaminathan M, Kantarjian HM, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo CD, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour EJ, Wierda WG, Ravandi F, Pinsoy MR, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 2017 Dec; 130(Suppl 1):723.

61. Naqvi K, Bravo GM, Pierola AA, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, NavalDaver, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, González GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 2017 Dec; 130(Suppl 1):4258.

62. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Takahashi K, Kadia T, Saenz DT, Nowak AJ, Sun B, Crews CM, Bhalla KN. Targeted Therapy for AML Expressing RUNX1 Mutation. Blood 2017 Dec; 130(Suppl 1):2472.

63. Ghorab A, Preetesh J, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, SrdanVerstovsek, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 2017 Dec; 130(Suppl 1):2868.

64. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, **Kadia TM**, Konopleva M, DiNardo CD, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. Blood 2017 Dec; 130(Suppl 1):3209.

65. Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gaisor Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 2017 Dec; 130(Suppl 1):2577.

66. Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 2017 Dec; 130(Suppl 1):256.

67. Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Estrov Z, Bose P, SherryPierce, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 2017 Dec; 130(Suppl 1):1434.

68. Assi R, Kantarjian HM, Khouri R, Ravandi F, Kebriaei P, Short NJ, Thomas DA, Garcia-Manero G, Champlin RE, Kadia T, Cortes JE, Jain N, Konopleva M, ZeevEstrov, Takahashi K, Sasaki K, Jacob J, Manzoor A, Garris R, O'Brien SM, Jabbour EJ. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood 2017 Dec; 130(Suppl 1):2597.

69. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu PC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, PadmaneeSharma, Pierce S, Brandt M, Pike A, Cortes JE, Kantarjian HM. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 2017 Dec; 130(Suppl 1):815.

70. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, JamesAllison, Sharma P, Kantarjian HM. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML. Blood 2017 Dec; 130(Suppl 1):1345.

71. Boddu P, Kantarjian HM, Ravandi F, Jabbour EJ, Daver N, Pemmaraju N, DiNardo CD, Verstovsek S, Alvarado Y, Borthakur G, Jain N, Konopleva M, BBenton C, Slack R, Patel KP, Garcia-Manero G, Cortes JE, Kadia T. Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and Cytarabine. Blood 2017 Dec; 130(Suppl 1):3898.

72. Rausch CR, DiNardo CD, Kadia T, Takahashi K, Jain N, Benton CB, AThompson P, Ohanian M, Covert W, Mace M, Marx K, Pemmaraju N, Daver N, Jabbour EJ, Cortes JE, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian HM. Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies. Blood 2017 Dec; 130(Suppl 1):1356.

73. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 2017 Dec; 130(Suppl 1):2584-2587.

74. Pemmaraju N, Boddu P, Kantarjian HM, Ravandi F, Lima MD, Champlin RE, Rondon G, Kadia T, Jabbour EJ, Garcia-Manero G, Cortes JE, HQazilbash M. Outcomes after Third Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Acute and Chronic Leukemias. Blood 2017 Dec; 130(Suppl 1):5551.

75. Patnaik MM, Alfonso A, Yalniz F, **Kadia TM**, Vallapureddy R, Jabbour E, Lasho TL, Hanson CA, Kantarjian HM, Tefferi A, Garcia-Manero G. Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases. Blood 2017 Dec; 130(Suppl 1):2964.

76. Yilmaz M, Devendra KC, Akosile MA, Khoury JD, Short NJ, Cortes JE, Garcia-Manero G, Ravandi F, Kadia T, Sasaki K, Konopleva M, Wierda WG, NitinJain, Verstovsek S, Estrov Z, Pierce S, O'Brien SM, Jabbour EJ, Kantarjian HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 2017 Dec; 130(Suppl 1):2712.

77. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour EJ, DiNardo CD, Daver N, Jain N, Pemmaraju N, Jorgensen JL, Wang SA, Andreeff M, Cortes JE, Kantarjian HM, Kadia T. Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities. Blood 2017 Dec; 130(Suppl 1):1419.

78. Sasaki K, Jabbour EJ, Khouri M, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Short NJ, Issa GC, Kadia T, Jones E, Garris R, Cortes JE, MO'Brien S, Kantarjian HM. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood 2017 Dec; 130(Suppl 1):2554.

79. Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Khoury JD, Ravandi F, JShort N, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, MO'Brien S, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 2017 Dec; 130(Suppl 1):1435.

80. Jain N, Jabbour EJ, McKay PZ, Ravandi F, Takahashi K, Kadia T, Wierda WG, Rytting ME, Nunez C, Patel K, Lu X, Tang G, Konoplev SN, AWang S, Han L, Thakral B, Roberts KG, Deshmukh A, Garris R, Jorgensen JL, AntonioCavazos, Verstovsek S, Garcia-Manero G, O'Brien SM, Cortes JE, Mullighan CG, Kantarjian HM, Konopleva M. Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial. Blood 2017 Dec; 130(Suppl 1):1322.

81. Boddu P, Gurguis C, Cortes JE, Akosile M, Ravandi F, Sanford D, Brandt M, Maduike R, Kadia T, Kantarjian HM, Borthakur G. Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood 2017 Dec; 130(Suppl 1):27.

82. Borthakur G, Kantarjian HM, DiNardo CD, Daver N, Jabbour EJ, Kadia T, Garcia-Manero G, Ravandi F, Pemmaraju N, Konopleva M, Ohanian M, Wierda WG, Jain N, Xiao L, Mukherjee P, Brandt M, Cortes JE. Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. Blood 2017 Dec; 130(Suppl 1):892.

83. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017 Dec; 130(Suppl 1):1275-1283.

84. Assi R, Kantarjian HM, Cortes JE, Kadia T, Pemmaraju N, Jabbour EJ, Jain N, Daver N, Uehara T, Owa T, Borthakur G. Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood 2017 Dec; 130(Suppl 1):1380.

85. Burger JA, Sivina M, Ferrajoli A, Jain N, Kim E, Kadia T, Estrov Z, Nogueras González G, Huang X, Ohanian M. Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2017 Dec; 130(Suppl 1):427.

86. Morita K, Wang F, Patel K, Bueso-Ramos C, Issa GC, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes JE, Garcia-Manero G, Jabbour EJ, Futreal A, Kantarjian HM, Takahashi K. Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia. Blood 2017 Dec; 130(Suppl 1):2667.

87. Assi R, Benton CB, Rawi AA, Chamoun K, Wang F, Pierce S, Patel KP, Hamilton BK, DiNardo CD, Garcia-Manero G, Kantarjian HM, Kadia T, SrdanVerstovsek, Andreeff M. JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition. Blood 2017 Dec; 130(suppl 1):1381.

88. Benton CB, Khan M, González GN, Nazha A, Piao J, Ning J, Aung FM, Jabbour EJ, Kadia T, Borthakur G, Ravandi F, Komrokji RS, Steensma DP, EDeZern A, Roboz GJ, Sekeres MA, Andreeff M, Kantarjian HM, Garcia-Manero G. Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome. Blood 2017 Dec; 130(Suppl 1):4265.

89. Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 2017 Dec; 130(Suppl 1):1379.

90. Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Wierda WG, Borthakur G, Naqvi K, Pemmaraju N, DiNardo CD, Daver N, Yilmaz M, Patel K, Linderman DB, Garris R, Jabbour EJ, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase. Blood 2017 Dec; 130(Suppl 1):143.

91. Khan M, Kantarjian HM, Ning J, Akosile M, Li W, Borthakur G, Jain N, DiNardo CD, Wierda WG, Ravandi F, Garcia-Manero G, Konopleva M, Kadia T, Pemmaraju N, Thompson PA, Daver N, Jabbour EJ, Cortes JE. Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia. Blood 2017 Dec; 130(Suppl 1):2882.

92. Issa GC, Kantarjian HM, Gonzalez NG, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood 2017 Dec; 130(Suppl 1):2091.

93. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Rubenstein SE, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger S, Butrym A, Gaidano G, Thomas X, Montesinos P, Rizzieri DA, Quick DP, Agura E, Venugopal P, JanakiramanSubramanian, Maness LJ, Robert D, Hicheri Y, Kadia T, Ravandi F, Marc. Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood 2017 Dec; 130(Suppl 1):891.

94. Jain P, Kanagal-Shamanna R, Kantarjian HM, Lucas F. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML. Blood 2017 Dec; 130(Suppl 1).

95. Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Borthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo CD, SherryPierce, Wierda WG, Kornblau S, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right? ; Blood 2017 Dec; 130(Suppl 1):4693.

96. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 2017 Dec; 130(Suppl 1):1514-1522.

97. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda WG. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood 2017 Dec; 130(Suppl 1):429.

98. Daver N, Boddu P, Garcia-Manero G, Ravandi F, Jabbour EJ, Borthakur G, DiNardo CD, Konopleva M, Pemmaraju N, Kadia T, Jain N, Pierce S, Flores W, Kornblau S, Hussain N, Ning J, González GN, Basu S, Cortes JE, PadmaneeSharma, Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. Blood 2017 Dec; 130(Suppl 1):2634.

99. Chamoun K, Kantarjian HM, Akosile MA, Assi R, Ravandi F, Borthakur G, Garcia-Manero G, Kadia T, Konopleva M, Estrov Z, DiNardo CD, Daver N, Pemmaraju N, Ferrajoli A, Burger JA, Wierda W, Jabbour EJ, Cortes JE. Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience. Blood 2017 Dec; 130(Suppl 1):1594.

100. Pierola AA, Assi R, Devendra KC, Abaza Y, Zahr AA, Chamoun K, GuillermoMontalban-Bravo, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, PPatel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood 2017 Dec; 130(Suppl 1):3852.

101. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, Devendra KC, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M, Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 2017 Dec; 130(Suppl 1):305.

102. Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Khoury JD, Jorgensen JL, Alvarado Y, Sasaki K, MarinaKonopleva, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WG, Estrov Z, Kornblau S, DiNardo CD, Ferrajoli A, Jacob J, Manzoor A, Garris R, O'Brien SM, Jabbour EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 2017 Dec; 130(Suppl 1):2576.

PATENTS

1. Glaxosmithkline Intellectual Propert (No. 2) Limited, assignee. Methods for Treating Cancer, Treating RAS-Mutated AML. United States of America patent US20130217710A1. Nov 04, 2011 (Issued).

Legend: 1 = Co-first authors, 2 = Co-second authors, L = Co-last authors, * = Trainee, ✉ = Corresponding author

Last updated: October 14, 2025